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1.1 DEFINITION AND HISTORY
Helicobacter pylori (Hp) has cohabitated with humans for over 50.000 years, thereby 
affecting directly more than half of the world’s human population. The Gram-ne-
gative spiral bacterium with its up to six unipolar sheathed flagella, has the unique 
ability to colonize the human stomach. Infection with Hp has been widespread and 
therefore geographic variations in the type of Hp have successfully been linked to 
the pathways of early human migrations. Direct evidence of early infections has 
been found in the form of Hp-DNA fragments in a Pre-Columbian mummy dating 
back to 1350 AD in current Mexico1. 
From 1875 onward, researchers have tried to reveal a positive association between a 
human infection with microorganisms and the development of peptic ulcers. In line 
with their hypothesis they already attempted treating ulcers with anti-microbial 
bismuth-containing compounds. In the 1950s Lykoudis found evidence that peptic 
ulcer disease and gastritis had in fact an infectious origin and he therefore decided 
to prescribe antibiotics to thousands of his patients2. 
More than 30 years later two Australian physicians, Barry Marshall (gastroenterologist) 
and Robin Warren (pathologist), were the first to describe the presence of a 
Campylobacter-like organism in the stomach of patients suffering from gastritis and 
peptic ulcers3,4. In 1984 Marshall started an attempt to assess Koch’s postulates for 
these diseases in piglets, but the experiment turned out unsuccessful. Eventually, in 
a bold approach to prove his hypothesis he infected his own stomach with a colony 
of the bacterium and fell ill himself. He underwent endoscopy and it was revealed 
that spiral bacteria were present in his antral biopsies and had caused his gastritis. 
This time, his experiment had succeeded and ever since, Hp has been recognized 
as a human pathogen. Marshall recovered from his gastritis by treatment with 
amoxicillin and a proton pump inhibitor, and he proved the causal relationship 
between his disease and Hp by fulfilling all four Koch’s postulates5,6. 
In recognition of their new discovery, Warren and Marshall were awarded with the 
Nobel Prize in Physiology or Medicine in 2005, particularly for their role in the obser-
vation of “the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer 
disease” as well as “further identification of Helicobacter pylori”. Initially, they named 
the bacterium “Campylobacter-like organism (CLO)”, because of its similarities with 
the Campylobacter species. Later the name was changed to Campylobacter pylori-
dis, Campylobacter pylori and, finally, it became known as Helicobacter pylori by 1989. 
Nowadays, Hp is recognized as one of the most important pathogens for a wide 
range of gastrointestinal diseases in the human species. Colonization commonly 
leads to gastritis and in 10-15% of the cases it progresses to peptic ulcer of the du-
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Fig 1: Panel (a) The number of entries in the scientific publications search engine Scopus 
(www.scopus.com) for the search strings “Helicobacter pylori” (black curve) and “Helico-
bacter Pylori children” (grey curve) as a function of the year of publication. Panel (b) The 
number of doctoral dissertations filed in PubMed (http://www.ncbi.nlm.nih.gov/pmc/) 
for the search strings “Helicobacter pylori” (black data) and “Helicobacter pylori AND child-
ren” (grey data) as a function of the year of publication.
odenum or the stomach, in less than 1% it leads to to mucosa-associated lymphoid 
tissue (MALT) lymphomas and in 1% to gastric carcinoma7,8. However, colonization 
of the human gastric mucosa does not necessarily result in the development of 
symptoms and typically more than 70% of infected people remain asymptomatic7.
The first report on Hp in the Netherlands, a letter to the Lancet by Langenberg et al 
in 1984, described gastric antral biopsies of 50 outpatients with upper abdominal 
complaints who were referred for upper gastrointestinal endoscopy9. The study 
unambiguously confirmed a positive association between colonization with Hp 
and gastritis and furthermore noted that Hp-associated gastritis may be present 
in apparently healthy individuals, thereby raising doubts about the clinical 
significance of Hp infections. 
In 1986, the first report on the isolation of Hp from the stomach of children was 
published by Hill et al 10. Cadranel and colleagues followed with the first European 
paper on Hp and children. They performed a small prospective study on twenty-
five children, eight of whom were found Hp-positive. The latter study confirmed 
the presence of Hp in children and established a positive correlation with epigastric 
pain and chronic gastric inflammation11. 
Currently more than twenty-five Helicobacter species have been identified in the 
gastrointestinal tract of animals and humans, whose infection correlates positively 
with the occurrence of gastrointestinal and systemic diseases12.
In figure 1 the rapid development of the scientific field of Hp-research, taking off at 
pioneering work of Marshall and Warren, is illustrated, as well as the relatively small 
fraction of that work that includes research on children.
1.2 CLINICAL FEATURES OF HELICOBACTER PYLORI INFECTION
1.2.1 Transmission and virulence factors
Generally Hp-infection is acquired during childhood and if not treated, the infection 
remains life-long. Spontaneous eradication in childhood appears to occur, but may 
be attributed to the unreported use of antibiotics to cure respiratory or parasitic 
diseases. 
The principal transmission route of Hp has not clearly been defined, nor has its 
source, but two models prevail: firstly, the vertical route in which parents infect 
their children, probably by gastro-oral, fecal-oral or oral-oral routes and secondly 
the horizontal transmission route in which intensive direct contact between infants 
and children or via for example dentists, endoscopists, or through environmental 
contamination of food and drinking water13-21. For the latter only indirect evidence 
exists in the presence of Hp-DNA in food and water. 
Coccoid morphological states of Hp have been detected in surface water, but so far 
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atrophy and intestinal metaplasia with development of gastric adenocarcinoma in 
adults. Gastric atrophy and metaplasia have also been described in children37. Few 
cases of gastric MALT-lymphoma in children have been reported, treated only with 
eradication medication for the Hp infection even in immune-compromised pedia-
tric patients. Reports of gastric adenocarcinoma in children are, however, rare38-44. 
1.2.4 Helicobacter pylori and extra-intestinal symptoms in children
Idiopathic thrombocytopenic purpura (ITP)
Several reports on recovery of thrombocytopenia after Hp eradication in adults and 
children with chronic ITP have been published45-48. 
In 47 Dutch children with chronic ITP the prevalence of Hp infection was 6.4% and 
all Hp positive patients achieved partial or complete remission of their ITP, however 
the follow-up time was rather short (six months) and unlike in adults the disease is 
characterized by spontaneous remissions in one-third of the children, particularly 
in the first year after the diagnosis. 
Gastroesophageal Reflux Disease (GERD)
In adults, Hp infection might have a protective role against GERD. The role of Hp in 
GERD in children remains controversial and currently insufficient data have been 
published 49-51. 
Short stature
There is insufficient evidence that Hp infection is causally related to short stature52. 
Many studies on this item have been conducted in countries where confounders 
with negative effects on growth in children might play a role: low socio-economic 
status, helminthic infections, iron deficiency anemia and malnutrition. In those 
studies height and weight were usually not expressed as standard deviation scores, 
local reference curves were not available (usually WHO reference curves were used), 
and parental heights were unknown. 
With respect to the possible pathophysiology, laboratory examinations have so far 
focused on Ghrelin, a strong growth hormone secretagogue, that is predominantly 
produced by entero-endocrine cells in the stomach. However, so far, most studies 
have been reported on total Ghrelin concentration, rather than the acylated form 
or the ratio between acylated and total Ghrelin. It is now generally believed that 
acylated Ghrelin is the active form of the hormone27,53-56.
Iron deficiency anemia
There are some plausible explanations for links between iron deficiency anemia 
could not be cultured in vitro, raising doubts about their potential for the transmissi-
on of the infection. Recognized risk factors for the infection onset are thought to be: 
- low socio-economic status and educational level
- living in a family with a high number of siblings (crowding)
- being born to an infected mother 
- the use of river or municipal water instead of spring water. 
The presence of bacterial virulence factors is one of the possible pathogenic 
mechanisms of Hp-induced gastroduodenal disease; putative virulence factors, 
especially CagA, VacA, bab A, hom B and OipA, are associated with the gene 
jph05632, that encodes for the cell envelope protein glycosyltransferase which 
appears important for the progression to peptic ulcer disease22-25. 
1.2.2 Helicobacter pylori and gastrointestinal symptoms in children
Bacterial virulence, host factors and potentially environmental exposures are 
considered to be key factors in the type of gastroduodenal inflammation and 
disease outcome that is associated with Hp-infection. It remains unclear as to: (l) 
why Hp causes symptomatic disease in only 20-30% of infected people; (2) how 
many of the organisms are needed to establish a persistent infection; and (3) who 
is prone for which disease phenotype. In children, antral predominant gastritis 
usually develops after colonization. Children may have transient impaired gastric 
acid secretion (hypochlorhydria), which, as is the case for adults, is thought to add 
to an increased susceptibility for enteric infections26,27. 
Although dyspepsia in adults is generally regarded to be caused by Hp, a specific 
clinical scenario of Hp infection in children is not known. The relation between 
recurrent abdominal pain (RAP) and Hp as described by Apley in 198528 has been 
assessed in many studies, but nevertheless the role of Hp in causing such symptoms 
has remained controversial29-32. A literature review over the years 1983-1998 found 
no specific correlation between RAP and Hp infection in children33. More recently, 
a systematic review confirmed the absence of such a correlation. Evidence was 
found for an association between epigastric pain and Hp infection in children 
except for children in primary care. Other gastro-intestinal symptoms as nausea, 
vomiting, regurgitation, diarrhea, flatulence or dyspepsia were not associated with 
Hp infection, but randomized control studies on this topic are needed34. 
1.2.3 Peptic ulcer
Duodenal and gastric ulcer disease in childhood are much less common in child-
hood than for adults and children develop gastric ulcers much less often than duo-
denal ulcers. Remarkably, the prevalence of non-Hp-associated ulcer disease seems 
to increase lately35,36. Longstanding Hp infections have been associated with gastric 
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developed countries where the prevalence of Hp infection in children is low, the 
prevalence is increasing with age because of a cohort effect 63,65,66. In institutions 
of intellectually disabled persons a relatively high prevalence has been found, 
including in the Netherlands15,66-68. 
Therefore, despite the decreasing prevalence of Hp infection in developed coun-
tries such as the Netherlands, Hp infections deserve attention and focus should be 
on those particular population groups, where the prevalence of Hp is relatively high. 
1.5 RE-INFECTION AND SPONTANEOUS CLEARANCE
Studies in adults in industrialized countries have shown that the rate of Helicobacter 
re-infection following an initial satisfactory eradication response is relatively 
low (3.4%), while the highest rates of recurrence (8.7%) have been reported in 
geographical regions with a lower development index and a very high prevalence69. 
Most cases of recurrence take place within twelve months after treatment. Studies 
using molecular fingerprinting techniques (e.g. polymerase chain reaction) favor 
the hypothesis that reappearance of a Hp strain identical to the pretreatment strain 
is defined as recrudescence of the Hp present in that patient prior to treatment and 
usually not as a true re-infection and describe lower recurrence rates 69-71. Niv et al 
described a literature search of 17 studies on Helicobacter pylori recurrence in adults 
in developed countries and in developing countries and found annual recurrence 
rates of 2.67% and 13.0%, respectively 72. Studies in children indicate a re-infection 
rate of 2.3-12.8% depending on the Hp prevalence in the country and the follow-up 
time (see table 1). 
Year Country Hp reinfection (%) Follow-up Months





1998 74 Japan 2.4 22
1999 75 Ireland/Dublin 11.5 24+/- 14
2002 76 Germany 2.3 15.5
2004 77 N-Ireland/ Belfast 2.4
2004 78 Estonia* 6.7 84
2005 79 Italy (South) 12.8 18-43
2006 80 France 5.4 148 patient years
Table 1 Re-infection rates in children
(4.3 if >5 years of age)
and Hp infection. One can imagine that the Hp infection can produce gastritis and/
or erosions and ulcers with chronic blood loss. Moreover, Hp gastritis may have 
reducing effects on gastric acid secretion and iron absorption. Another mechanism 
could be utilization of iron by Hp for its growth.
Confounders in studies on Hp and iron deficiency anemia are low socio-economic sta-
te, poor hygienic standards and malnutrition. Only one study described an increasing 
blood hemoglobin value in Hp-positive children after eradication therapy. More well-
designed studies in developed as well as developing countries would be useful 57-59.
Recent guidelines recommend that in children with refractory iron-deficiency 
anemia, testing for Hp infection may be regarded after other causes have been 
ruled out 52.
1.3 DIAGNOSIS
So far, guidelines for the management of Hp infection in children recommend en-
doscopy to exclude other pathological causes for the child’s symptoms52. The reaso-
ning behind this recommendation is that no specific complex of clinical symptoms 
and signs has been established for children. Reflux-esophagitis, eosinophilic eso-
phagitis, celiac disease or Crohn’s disease could cause symptoms similar to those 
caused by gastritis or ulcer and can only be ruled out by endoscopy. The current 
gold standard for the detection of an Hp infection is endoscopy with gastric bi-
opsies for histology, a rapid urease test and a culture with susceptibility testing. 
Cultures of gastric tissues have a specificity of 100%, but a relatively low sensitivity 
of 38-80%. PCR testing in gastric tissue can detect genes associated with virulence 
factors and antibiotic resistance. As endoscopy is both invasive and expensive and 
particularly in children usually requires deep sedation or anesthesia, non-invasive 
tests have been developed. The 13C-urea breath test (UBT) and the monoclonal 
stool test have been validated well in children older than 6 years for the detection 
as well as the eradication control of Hp. Unfortunately these non-invasive tests have 
not sufficiently been validated in younger children, below the age of 6 years60-62.
1.4 EPIDEMIOLOGY AND PREVALENCE
The prevalence of Hp infection varies greatly between developing and developed 
countries, respectively 90% versus 40% at the age of 40 years, and is declining 
worldwide over the last decades63. The prevalence of Hp in children in the 
Netherlands is 1.2% at the age of 2-4 years and 9% at the age of 7-9 years and 





















































200197 1995-2000 North-East 2.1 (5946) 18.8 (5946)
200398 1995-2000 Zaandam* 4.8 (724) 25.8 (727)
200599 1998-2003 Den Bosch* 3  (959) 14 (960)
2006100 1997-2002 Doetinchem* 1 (1123) 14.4 (1125)
Table 2 Hp resistance to Clarithromycin and Metronidazole in Dutch adults (1993-2003)
to amoxicillin is very low in Europe. More recently alternative therapeutic regimens 
have been introduced including sequential therapy and quadruple therapy90-92, to 
overcome the problems of resistance. So far, promising results have been obtained, 
although the knowledge on local resistance rates remains key to effective therapy. 
In most Northern and Western European countries antibiotic resistance does 
not play a major role, but in Southern-Europe, Africa and Asia high resistance 
percentages have been found for clarithromycin and metronidazole. The relatively 
low prevalence of resistant strains in our country (1-5 and 7-33% to clarithromycin 
and metronidazole, respectively) has led to guidelines on test-and-treat-policy 
for adults below the age of 45 years (see table 2). However resistance rates are 
increasing in Dutch adults, and therefore surveillance will remain necessary in 
order to maintain this regimen for the future.
1.6 GUIDELINES FOR DIAGNOSIS AND TREATMENT
1.6.1 Adults
Updated guidelines on behalf of the European Helicobacter Study Group (Maastricht- 
l11 Consensus Report) for management of Helicobacter pylori infection in adults have 
been published in 200781. One small paragraph in that report provides directives on 
Hp testing in children with recurrent abdominal pain and iron deficiency anemia. In 
the fourth edition of the Maastricht consensus report (2012) no recommendations on 
Hp in children have been included 82. The Dutch standard for general practitioners 
(NHG-standard) lacks recommendations for treating children with Hp infection81,83. 
1.6.2 Children
Dutch evidence-based guidelines for Hp infection in children do not currently 
exist. Up to now, directives from Ireland and Canada have been used by the Dutch 
Society of Pediatrics. Recently NASPGHAN (North American Society Pediatric Gas-
troenterology, Hepatology and Nutrition) and ESPGHAN (European Society Pedia-
tric Gastroenterology, Hepatology and Nutrition) published joint evidence-based 
clinical guidelines for the diagnosis and treatment of Hp infection in children in 
North-America and Europe 52,84-87. In these guidelines it is recommended that the 
initial diagnosis of Hp infection should be based on either histopathology plus a 
rapid urease test on the biopsy or a positive culture. In contrast, the recommen-
dations for adults suggest a test-and-treat regimen, based on one positive non-
invasive diagnostic test under strict conditions. “Test-and-treat” is definitely not 
recommended in children. First-line eradication therapy usually comprises triple 
therapy (protonpump-inhibitor + amoxicillin+ clarithromycin (or metronidazole) or 
bismuth salts + amoxicillin+ metronidazole during 7-10 days, or sequential therapy. 
The 13C-urea breath test and the monoclonal stool test are reliable non-invasive 
tests to determine whether Hp has been eradicated 4-8 weeks after completion of 
therapy.
In the Netherlands the publication of evidence based guidelines is scheduled for 
2012.
 
1.7 RESISTANCE TO ANTIBIOTICS
Antibiotic resistance of Hp is one of the main reasons for eradication failure in adults 
as well as in children and there is evidence that the prevalence of resistance is 
increasing. Generally the prevalence of resistance to macrolides is higher in isolates 
from children than those from adults as opposed to results for metronidazole88. In 
a French study on 27 treatment regimens a global failure of 25.8% was found and 
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1.8 AIM, RESEARCH QUESTIONS AND OUTLINE OF THE THESIS
Introduction of non-invasive diagnostic tests and test-and-treat policy have led 
to a decreasing prevalence of the infection and its main complications. However, 
the interest of the scientific society working on Hp has mainly highlighted work 
on adults, as can be seen from Figure 1. There are important reasons for pediatric 
gastroenterologists to focus on Hp: 
-   the continuous immigration of children from relatively high-prevalence coun-
tries (particularly Turkey, Morocco, Somalia and China), as well as the adoption 
of children from abroad. As the infection is usually acquired early in life, these 
children may already have been infected in their respective country of origin.
-   the increasing resistance rates of the bacterium, which diminishes the eradica-
tion rate and which could be the reason for recrudescence of the infection after a 
negative eradication control.
-   the awareness that the first stage of the infection in humans occurs usually during 
childhood. The discovery of this should have given an impulse on the study of Hp 
in children.
The aim of this dissertation is to present scientific data on the prevalence and treat-
ment of Hp infection in children. 
The thesis is divided in four parts:
Section A (chapters 2 and 3) provides an overview of the literature on Hp in pediatrics 
published between 2005-2006 and 2009-2010 respectively.
Section B (chapters 4-6) focuses on the prevalence of Hp infection in children 
and discusses its complications. Chapter 4 contains data on the prevalence of Hp 
infection in young Dutch children within the general population. Chapter 5 de-
scribes aspects of one of the severe complications of Hp infection in children, ulcer 
disease, in a European-wide multicenter study. In chapter 6 results of a prevalence 
study of Hp infection in a developing country (Bandung, Indonesia) are described. 
Here a new monoclonal stool antigen test was used for a group of 150 young 
Indonesian children. 
Section C (chapter 7) discusses the main reason for eradication failure, the antibiotic 
resistance of Hp, for both adults and children in the Netherlands. 
The results of this thesis are discussed in Section D, chapter 8 and in this chapter 
also considerations about future scientific research on Hp are addressed.
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INTRODUCTION
In 2005 “the Nobel Prize in Medicine or Physiology” was awarded to Marshall and 
Warren for the discovery in 1982 that most peptic ulcers are caused by an infection 
with Helicobacter pylori 1-3. It took a further 10 years before literature about H. pylori 
infection in children was published. It is now well accepted that the bacterium is 
usually acquired during childhood, mainly from the mother via vomitus or fecal 
oral route 4-9. Great strides have been made since. In July 2005, the Canadian 
Helicobacter Study Group published an evidence-based Consensus Update on the 
approach to H. pylori infection in children and adolescents, adopted in 2006 by 
members of the H. pylori Pediatric Task Force in the U.S.A 10. We hope to reach a 
combined NASPGHAN-ESPGHAN consensus before the World Congress of Pediatric 
Gastroenterology, Hepatology and Nutrition meeting in Brazil in 2008. 
BASIC RESEARCH 
Peeters published an excellent overview about the peptide ghrelin, related to 
motilin which has been suggested to have “ saginary” effect in H. pylori infection. 
H. pylori infection could influence ghrelin-secreting cells, and impairs the secretion 
of histamine, pepsin and gastric acid 11. Eradicating H. pylori can lead to a rise in 
plasma ghrelin, which could promote the development of obesity, increasing the 
risk of reflux disease and subsequent risks of Barrett’s esophagus and esophageal 
adenocarcinoma. The suggestion that H. pylori-eradication may contribute to the 
obesity epidemic in industrialized countries is an interesting hypothesis to ponder! 
Ernst highlighted an article of Velin et al about the essential role of mast cells as 
mediators in experimental Helicobacter clearance by vaccination because mast 
cells-deficient mice could not be protected by immunization; this could be changed 
by reconstituting them with bone marrow-derived mast cells 12,13. 
Ceponis and Jones summarized in the Canadian H. pylori Update the current 
knowledge of specific H. pylori factors. H. pylori infection can modulate signal 
transduction pathways in multiple host cell types and specific bacterial factors can 
activate certain cascades in the mucosa. The bacterium can also lead to opposing 
effects: anti-apoptotic by inducing NF-kB activity and can suppress interleukin (IL)-
4 induced signal transduction 14. 
PREVALENCE, INCIDENCE AND TRANSMISSION
The prevalence of H. pylori infection is declining in developed countries. Never-
theless, immigrants and indigenous people continue to carry a high burden of 
ABSTRACT
This review summarizes the literature on Helicobacter pylori infection in childhood between 
April 2005 and March 2006, and includes guidelines of the Canadian Helicobacter Study 
Group Consensus Conference, non-invasive tests, optimum therapy regimens and problems 
with resistance, and reviews on immune mechanisms in the gastric mucosa that may lead to 
the development of an effective vaccine. 
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MOTHER TO CHILD TRANSMISSION
The role of infected mothers has been described in 2002 4 and stated by Konno et 
al 5 in a 5-year follow-up study of 44 children. They collected gastric juice samples for 
culture and DNA-analysis from 69 H. pylori-positive mothers. None of the children 
acquired H. pylori during the first year of life. Five children were tested positive 
within 5 years by serology and stool antigen test. Strains of the 5 positive children 
exhibited DNA fingerprinting patterns identical to those of their mothers.
In a follow-up of children up to 36 months old using monoclonal stool test, infected 
mothers were the main source of H. pylori infection of their children, as the mother, 
being primary carer, has closer contact with the infant than the father in the first 
year of life 8.
SYMPTOMS
Abdominal pain
The association between chronic abdominal pain and H. pylori infection is still hotly 
debated. 
Tindberg et al investigated the association between type-specific H.pylori infec-
tion and gastrointestinal symptoms in a cross-sectional study of Swedish school-
children. Infection was investigated by IgG-antibodies in serum and confirmed by 
immunoblot and UBT. Abdominal pain was reported by 63% of the children and 
recurrent abdominal pain (RAP) by 13%; 16% were infected; 73% of these children 
had CagA antibodies and 59% VacA antibodies. The authors did not find a positive 
association between H. pylori-status and occurrence of abdominal pain: RAP was 
unrelated to the infection (OR 1.0; 95% CI 0.5-2.1), when adjusted for sex, age and 
family background. The prevalence of RAP was lower in children with CagA+ and 
VacA+ infections than among uninfected children 20. 
Yang et al investigated 1271 children with questionnaires to define RAP or short-
term RAP (SRAP) with pain duration from 2 weeks to 3 months. All children with RAP, 
SRAP or a combination were tested for H. pylori by serology. Prevalence rates of RAP 
and SRAP were 9.8 and 5.5%, respectively. Children with SRAP had a higher anti-H. 
pylori seropositivity rate than those with RAP and controls. One year later 71% of the 
seropositive children became symptom-free, regardless of persistence of H. pylori. 
Infection was more frequently found in children with SRAP 21.
The subcommittee on chronic abdominal pain reviewed the predictive value of la-
boratory tests. The authors conclude that the coexistence of abdominal pain and 
an abnormal test result for H. pylori infection does not necessarily indicate a causal 
relation between the two 22.
H. pylori infection and disease in their children. In Canada, the immigrant 
population comprises 200.000 individuals per year. The prevalence in children 
undergoing gastrointestinal endoscopy from 1990 to 1994 was 26-43%: it has now 
decreased to about 5%. Jacobson also highlights the study by Miller (2003), in 
which adopted children have a seroprevalence of 16%, 20% and 49% respectively. 
He suggests more studies in children with different geographic, socioeconomic 
and ethnic backgrounds using validated screening tools to see whether eradication 
is associated with reduced H. pylori-related diseases or with significant benefit in 
adulthood 15.
New data on prevalence come from Asia: Nizami found that early colonization 
in 148 children showed a decreasing trend with increasing age (80% at 1 month 
of age, 67% at 9 months). The researchers did not, however, study children over 
1 year of age 16. Singh et al. determined prospectively the prevalence of H. pylori in 
58 children with upper abdominal pain (UAP) and 182 controls. In the UAP-group, 
the prevalence of H.pylori was 53.4%, in the group children without UAP, 28%. The 
overall prevalence increased with age; 82% of the children with UAP were negative 
after eradication, with a further 18% after second eradication therapy. All treated 
children with UAP remained symptom-free for two years. They concluded to 
a strong link between H. pylori infection and UAP 17. Alborzi et al collected stool 
samples from children from different age groups in Shiraz and found prevalence 
rates of H. pylori of 82, 98, 88, 89 and 57% in age groups of 9 months, and 2, 6, 10, and 
15 years, respectively. There was a significant decrease in the 15 year old teenagers 18.
Wong et al 19 studied the prevalence of H. pylori in symptomatic Chinese children 
retrospectively from 1997-2004 to assess the impact of an aggressive eradication 
program. From 159 patients undergoing gastroscopy, 119 had gastritis, 13 had peptic 
ulcer disease (overall rate of proven H. pylori infection 25.6%). They did not find a 
significant decrease of overall prevalence (33% in 1997, 27.7% in 2004), but reported 
that increasing age was significantly associated with a higher risk of infection. Their 
hypothesis was that eradication efforts were unsuccessful, possibly due to Chinese 
eating habits (cross infection from sharing chopsticks). 
Recently, Rowland et al published a prospective study of age-specific incidence of 
H. pylori infection in children between 24 and 48 months of age, by using 13 C-urea 
breath test (13 C-UBT). They found a positive test in 28 of 327 index children (8.6%) 
at baseline assessment; during the next 4 years 20 children became infected. As in 
previous studies, the infection was acquired at a very young age with a declining 
risk after 5 years of age. Risk factors were having an infected mother, an infected 
older sibling, and delayed weaning from a feeding bottle 9.
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EXTRADIGESTIVE MANIFESTATIONS
In the pediatric age group the following have been reported: anemia, idiopathic 
thrombocytopenic purpura (ITP), short stature, diarrhea, food allergy and sudden 
infant death syndrome, some without sufficient evidence 29.
Idiopathic thrombocytopenic purpura 
Although the same author in an earlier study in 2003 reported an increased 
incidence of H. pylori in patients with chronic ITP, in a prospective study, Jaing et 
al did not find evidence of an association 30,31. Sherman and Lin mentioned the 
potential for molecular mimicry with antiplatelet antibodies, recognizing the CagA 
protein of H. pylori as a possible explanation for an association. The Canadian group 
did not include ITP as extradigestive manifestation in the recent guidelines 29.
Anemia
The Canadian Consensus Group concluded that there is sufficient evidence available 
to consider unexplained sideropenic anemia as an extradigestive manifestation 
and to consider test-and-treat strategy in such cases.
One recent study from India reported reduced hematological response to iron 
supplementation in asymptomatic children with H. pylori compared to children 
without infection. The mean serum ferritin was similar at admission and improved in 
both groups of children, but infection had a significant adverse effect on response 
to iron therapy 32.
Growth 
In 2005 two studies have been published about the relationship between growth and 
H. pylori infection: Sood et al compared height, weight and body mass index (BMI) of 
97 positive children with dyspeptic symptoms to 160 children with dyspepsia without 
infection. They found no significant difference between mean weight and height SD 
score in the infected and not infected group 33. Mera et al investigated, whether a 
newly acquired infection affects height and weight within 16 months by performing 
UBT and anthropometry every 2-4 months. Authors observed a significant decrease 
in growth velocity during the first 4 months after infection and the children showed 
no height catch-up. Infected children had a small decrease in weight, in comparison 
to non-infected children. Their conclusion is that H. pylori infection causes a non-
transient negative effect on height and weight in Colombian children 34.
In the Canadian Consensus Report, Sherman and Lin did not find firm evidence for 
the role of H. pylori infection in growth 29.
Non-ulcer dyspepsia (NUD)
Kalach et al 23 investigated 100 children older than 6 years with NUD, by endoscopy 
for epigastric pain in a prospective double-blind study; 26 children were infected. 
No differences in age or symptom characteristics between infected and non 
infected children was found, except for epigastric pain during meals, which was 
more frequent in non-infected children. They concluded that H. pylori-infected 
NUD-children had no specific symptoms.
At the end of 2005 Talley et al published a review on the evaluation of dyspepsia in 
adults. As is the case in adults, the test-and-treat strategy is not recommended in 
children with dypepsia: endoscopy is mandatory in this age group 24.
Gastroesophageal reflux disease 
The question is whether testing for H. pylori is necessary in infants with gas-
troesophageal reflux disease (GERD). Moayyedi reviewed the literature about 
the association between GER and H. pylori infection. His conclusion is that 
H. pylori-induced hypochlorhydria is frequent in adults, but rare in children and 
that therefore eradication is unlikely to have an important impact on GERD or 
protonpump inhibitor (PPI) efficacy in this age group. His advice is that child-
ren with GERD, diagnosed clinically or by pH studies, do not need to be tested for 
H. pylori, unless they have endoscopy and have proven infection 25. 
As GERD has been suggested as a contributing factor to otitis media, Bitar et al 
investigated the possibility of a role of H. pylori in middle ear disease in children, 
however, all 28 middle ear fluid cultures and polymerase chain reaction (PCR) were 
negative; also 13 adenoids were negative for H. pylori by PCR. Seven of 18 patients 
had symptoms suggestive of GERD preceding the study, but this had no impact on 
the results of the study 26.
Gastritis
Leung et al emphasized the diagnostic role of macroscopic observation of the 
gastric mucosa at endoscopy 27. Ricuarte et al studied the prevalence of atrophic 
gastritis in childhood with this hypothesis. Of 173 children, atrophic mucosa near 
the antrum-corpus border was present in 16% of the positive children, primarily 
as pseudo pyloric metaplasia (median age 15 years). As gastric atrophy occurs in 
infected children living in countries with a high incidence of gastric cancer they 
recommend that biopsies be taken near the lesser and greater curvature just 
proximal to the anatomical antrum-corpus border as well 28.
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Helicobacter spp. were identified in three. They suggested that transient positive 
stool tests are common and represent H. pylori in majority of cases; however some 
positive stools may represent other Helicobacter species 39.
Hauser et al compared a multi-step polyclonal versus one-step monoclonal enzyme 
immunoassay in stool with 13C-UBT in 43 children; 18 children were positive (posi-
tive UBT). The polyclonal stool test had a comparatively good sensitivity, but lower 
specificity compared to UBT. The one-step monoclonal rapid test also had a compa-
rable sensitivity and specificity, when a weakly positive test (visual interpretation) 
was considered negative 40. 
Kalach et al tested the rapid monoclonal stool test in 128 children and observed the 
highest performance of the test in children older than 10 years (sensitivity 100%), in 
contrast with 75% in those younger than 5 years; in this study he found 11 discordant 
results of the test compared with gold standard 41.
Antos et al evaluated a novel rapid monoclonal one-step immunochromatograp-
hic assay for detection of stool antigen and concluded that this quick test shows a 
good interobserver agreement, but equivocal results in 5% 42.
More studies with quick tests in stools are needed; however, in settings without 
possibilities for UBT or enzyme immunoassay, the immunochromatographic test 
could become an alternative to assess H. pylori status pre- or post-treatment in 
children 36. 
A study from Thailand evaluated the performance of a rapid office-based serologic 
test (Assure™ , Genelabs Diagnostics, Singapore) and the immunoblotting for the 
diagnosis in symptomatic children. The sensitivity of the test was 96%, specificity 
94.6% versus immunoblot, 100 and 96,2% respectively, so the test seems to be reli-
able for the diagnosis of infection in Thai children 43.
The above Assure test was also evaluated in 130 children by Pelerito et al. They 
found a lower sensitivity (75.7%) and a specificity of 95.0%, which increased to 98,6 
and 95% when a longer reading time of 45 minutes was considered 44.
The use of serology-based tests could not be advocated by the Canadian Consen-
sus group anymore because of their low accuracy in young children. In a study from 
Lithuania a seroprevalence of 57% was found; following gold standard it was 79% 45.
Invasive diagnostic methods require endoscopic biopsies and include rapid urease 
testing, histology and culture. When used in combination, these tests are still con-
sidered the “gold standard” for the diagnosis of H. pylori in children. The added 
advantage of this approach is the detection of upper gastrointestinal pathologies 
including complications of the infection, such as nodular gastritis, peptic ulcer 
disease, gastric cancer and MALT-lymphoma. Biopsies are necessary for determina-
tion of antibiotic resistance and virulence factors 46,47.
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Other reported manifestations such as food allergy, diarrhea and sudden infant 
death syndrome were not added to the list of extra intestinal symptoms by the 
Canadian group. 
DIAGNOSTIC TOOLS
None of the non-invasive tests are 100% specific and sensitive. 13C-Urea breath 
test is reliable for detecting infection in children older than 6 years of age but can 
give false-positive results in younger children 10. There was a small number of very 
young H. pylori-positive patients in these studies, making it difficult to validate new 
diagnostic tests in this age group.
Mégraud et al reported in a multinational study on four non-invasive tests that UBT 
had the best sensitivity in all age groups, followed by serology, stool antigen test 
and antibody detection in urine. In all tests, except the stool test, better sensitivity 
was observed with increasing age. The urine office test exhibited a very low sensi-
tivity 35.
The Canadian Consensus group concluded that UBT is currently the best available 
noninvasive diagnostic test in children and published a list of variables that may 
influence the results of the test 10,36.
Recently Nugalieva et al raised attention to the problem of false-positive UBT and 
recommended confirmation of a single positive test in low-prevalence populations 
by using a test that measures a different parameter (UBT confirmed by stool test) 37.
The polyclonal antibody-based stool antigen test (HpSA) is not as reliable as UBT, 
neither pre-treatment nor after eradication 35, but monoclonal stool antigen tests 
perform as well as UBT. The Canadian group judged that it was too premature to 
recommend stool antigen testing as an alternative to UBT, but in settings where 
the breath test is not available for children, the monoclonal test is an excellent al-
ternative to assess H. pylori status pre-and post-treatment 36. Raguza et al evaluated 
127 children to compare the accuracy of a modified polyclonal stool antigen test 
with the gold standard. However, there were no H.pylori positive infants below the 
age of 2 years in his study. Three patients showed false-positive results and two 
false-negative results for the HpSA. The sensitivity of the HpSA test was higher in 
children in the age of 6-18 years (100%) than in 2-6 years (80%). The specificity was 
respectively 95-100% and 96.4% 38. 
Haggarty et al also used the polyclonal HpSA test in a study of stool samples 
from children at two time points, 3 months apart; PCR was performed on all 26 
pairs reverting from positive to negative (transient positives), all four persistent 
positive pairs and 10 randomly selected persistent antigen-negative pairs. In 15 of 
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TREATMENT 
Based on the data in pediatric literature and in adults the Canadian Consensus 
group decided that the recommended first-line eradication therapy should include 
a PPI and clarithromycin, combined with either amoxicillin or metronidazole. Hi-
gher eradication rates may be achieved by a longer treatment regimen (triple the-
rapy 14 days instead of 1 week) 10.
A randomized clinical trial from Italy showed that a novel 10-day sequential treat-
ment (omeprazole plus amoxicillin for 5 days, followed by omeprazole plus clari-
thromycin plus tinidazole for another 5 days) achieves a significantly higher eradica-
tion rate than standard triple therapy (omeprazole, amoxicillin and metronidazole) 
for one week 48.
Khurana et al summarized data from studies that have examined treatment effi-
cacy, safety, drug resistance and reinfection rates. Treatment efficacy was reduced 
in the presence of metronidazole and/or clarithromycin resistance. Resistance to 
metronidazole and/or clarithromycin is common and no therapy has yet been iden-
tified as safe and consistently effective to eradicate H. pylori infection 49.
Elitsur et al assessed the resistance rate against clarithromycin in 16 positive child-
ren by the FISH technique in gastric biopsies; the primary resistance rate in this 
small group was very high (31-38%) 50; Boyanova et al found primary clarithromycin 
resistance in 12.5% and metronidazole resistance in 15% of Bulgarian children 51. Re-
cently Koletzko et al assessed the bacterial resistance in children from 14 European 
countries. She reports an overall resistance to clarithromycin of 24%, to metronida-
zole 25%; and to amoxicillin 0.6%, the last being very low 52.
 A Russian group investigated failure of triple therapy; patients were randomized to 
receive a 2-week course of bismuth, amoxicillin with either nifuratel or furazolidone 
plus omeprazole. Both schemes produced good cure rates, but nifuratel is prefer-
red because of lower frequency of side-effects. Antibiotics susceptibility tests have 
not been carried out in this study 53.
The Canadian group discussed whether treatment of H. pylori in childhood will alter 
the two-to sixfold increased risk of developing gastric cancer among infected pa-
tients. A population-based test-and-treat policy in children is not justified, except 
in groups with a high risk of developing gastric cancer (Japanese or those with a 
strong positive family history) regarding negative cost-benefit analysis 54.
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The relationship between apoptosis and Helicobacter pylori remains an important 
aspect of H. pylori pathogenesis research. In a Polish cohort of children with 
symptomatic H. pylori infection and gastritis, Fas receptor expression was increased in 
the CD4+ T cell population in the lamina propria at diagnosis and Fas antigen expression 
was significantly decreased in both epithelial cells and mucosal lymphocytes 
following successful eradication1. The authors speculate that apoptosis of CD4+ 
T cells could contribute to bacterial persistence in the mucosa.
Studies of the spectrum of H. pylori genetic variability between childhood and 
adult isolates may help to elucidate age-specific microbial genetic factors involved 
in pathogenesis. Rick et al suggested that in situ hybridization techniques, which 
reflect in vivo gene transcription, may be superior to testing isolates for CagA in 
vitro and used this method to confirm the association between gastric mucosal 
H. pylori CagA expression and pediatric gastro-duodenal ulcer disease 2. While 
children had a higher prevalence of CagA+ strains compared to adults in one study 
from China, CagA was not shown to influence their disease phenotype 3. H. pylori 
strains from symptomatic children in the USA and Greece were more likely to be 
CagA- and lack a functional CagPAI, although the USA isolates were more likely to 
retain outer membrane protein (OMP) and adherence gene expression than adult 
strains, a possible microbial advantage for early life infection and colonization 4,5. 
The adherence properties and expression profile of OMP genes of H. pylori isolates 
from 200 symptomatic patients were characterized by Odenbreit et al 6. Apart from 
AlpA and AlpB, the expression of other OMPs was variable. In vitro interleukin (IL)-8 
expression was again shown to be increased by CagA+ strains, while co-expression 
of OipA, but not OipA alone, further enhanced IL-8 secretion. The presence of the 
putative virulence factor gene IceA, while common, was not predictive of the extent 
of inflammation on histology in Slovenian children; CagA and VacA s1 genotypes 
were associated with more severe gastritis and greater bacterial density 7.
Autophagy, an evolutionary conserved process in eukaryotic cells, is an integral 
component of our innate immune system and is implicated in the pathogenesis 
of a number of gastrointestinal diseases 8. H. pylori VacA toxin has recently been 
shown to induce autophagy in gastric cells in vitro, a potential host defense 
strategy to limit toxin damage, but auto-phagosome formation may also facilitate 
bacterial replication and survival 9. H. pylori has also been shown to multiply in 
autophagosomes in macrophages, suggesting that it may be subverting autophagy 
for its own benefit 10.
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ABSTRACT
Pediatric-based Helicobacter pylori research continues to contribute significantly to our 
understanding of both clinical and pathophysiological aspects of this infection. Here, we 
review the published pediatric H. pylori literature from April 2009–March 2010.
Analysis of pediatric H. pylori strains continues to suggest that CagA+ and CagPAI competent 
strains are less prevalent than in adult isolates. Studies from the Middle East report a high 
H. pylori prevalence and intrafamilial transmission. Data continue to show a lack of association 
between H. pylori and recurrent abdominal pain of childhood, gastroesophageal reflux 
disease, and growth retardation.
Recent probiotic trials have not shown a benefit on H. pylori eradication in children, while 
sequential therapy remains an attractive therapeutic eradication strategy in children, which 
requires validation in different geographic regions.




The discussion about the association between recurrent abdominal pain (RAP), 
epigastric pain, unspecified abdominal pain, and H. pylori infection in children 
continues. Thakkar et al published a retrospective study on upper digestive 
endoscopy in 1191 children with abdominal pain; 55 children (5%) were diagnosed 
with H. pylori infection, the second most common diagnosis after reflux esophagitis 
(23%) 20. They agreed that earlier studies did not show a causal relation between 
H. pylori infection and abdominal pain in absence of ulcer disease, but conceded 
that there is a trend to offer eradication therapy once the H. pylori infection has 
been diagnosed. In a meta-analysis, Spee et al found no association between RAP 
and H. pylori infection in children and limited evidence for an association between 
unspecified abdominal pain and H. pylori in referred, but not in primary care patients 
21. Although current evidence does not support infection as a significant cause of 
common symptoms in children, guidelines on H. pylori screening in children are 
contradictory 22,23. For example, discrepancies exist between the earlier European 
Pediatric Task Force on H. pylori report and the more recent Maastricht III statement, 
which suggests that although RAP is not an indication for a test-and-treat strategy 
in children, those with upper gastrointestinal symptoms should be tested after 
exclusion of other causes of symptoms 23,24.
Peptic Ulcer
H. pylori infection is the most important cause of primary duodenal ulcers in children. 
A retrospective study of differences between H. pylori+ and H. pylori- primary ulcers 
in 43 Chinese children diagnosed >8 years showed that boys vs. girls (91.3 vs. 50%) 
and older children (12 vs. 10 years) were more likely to have H. pylori+ ulcers (53.5%) 25. 
In the H. pylori- group, ulcer recurrence was more common. In an editorial comment, 
Oderda et al noted the emergence of ‘a new disease’: H. pylori-negative gastric 
or duodenal ulcer, occurring more frequently in younger children, without gender 
preference and tending to have a higher recurrence rate 26. Rick et al investigated 
51 children, of whom six had gastric ulcers (all H. pylori+) and 11 had duodenal ulcers 
(10 H. pylori+), and found H. pylori by 16S rDNA and CagA PCR significantly higher in 
children with ulcer compared with normal children 2.
Gastroesophageal Reflux Disease (GERD)
The role of H. pylori in GERD remains controversial, limited by sufficient published 
data in children. Both a positive and negative association between H. pylori and 
GERD was reported recently 27,28. Moon et al found reflux esophagitis in 13 of 16 
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EPIDEMIOLOGY AND TRANSMISSION
The estimated 7.1% prevalence of H. pylori infection in asymptomatic children in 
the Czech Republic is among the lowest reported in Europe 11. Sykora et al found a 
positive association with increasing age, the number of children in the household 
(OR 4.26,CI 1.91–9.80), lack of formal education of the father (OR 0.23; CI0.18–0.64), 
and institutionalization (OR 6.33; CI 2.25–26.50). Their findings are consistent with 
improving trends in living and housing conditions in recent years and with de- 
creasing family size.
While the prevalence in Western countries and America is decreasing, the high 
prevalence in Asia remains. Malekzadeh et al using stool antigen and serology 
testing, reported a high prevalence of H. pylori infection in 592 Iranian children 
from Shiraz and 386 children from Rafsanjan (82% and 47%, respectively,) 12. Iran 
and Iraq have a high prevalence of CagA+ H. pylori 13. In a study from Pakistan, a 
seroprevalence of 47% among 1976 children (1–15 years) was reported. The father’s 
educational status, crowding, and increasing age, were the main factors influencing 
sero-positivity 14.
Understanding the intrafamilial spread of H. pylori is an important aspect of 
transmission research. A study of 100 children with abdominal symptoms (44 
H. pylori+) found a higher percentage of H. pylori infected siblings, mothers, and 
fathers, tested by urea breath test (UBT), among H. pylori+ than H. pylori- index 
cases (p < .001, p < .001 and p < .035, respectively) 15. Each H. pylori+ child had at 
least one infected family member, implicating the family as the source of H. pylori 
infection in children. Nahar et al found evidence of intrafamilial transmission of 
H. pylori by characterizing H. pylori in 35 families, including 138 family members, 
using DNA fingerprinting 16. Forty-six percent of strains from the mothers shared 
related genotype with strains from their children. Only 6% of parents shared a 
related genotype, suggesting mother– child transmission as the most probable 
transmission route.
In a study from Iran, Amini et al described the association between H. pylori infection 
and eating habits (sharing plates, glasses, and spoons) and found a significantly 
higher prevalence of H. pylori infection in families where common dishes were 
used17.
Travis et al used UBT at 6-month intervals from birth to 24 months to 
describe possible water-borne transmission of H. pylori in a cohort study of 
472 children from Mexico and Texas 18. Their results provide some support for water-
borne transmission. On the other hand, Vale and Vitor reviewed water- and food-
borne transmission of H. pylori and concluded that the principal transmission route 
remains to be clearly defined 19.
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al did not find a significant association between anemia and growth retardation; 
a subgroup analysis did suggest an association between endoscopic mucosal 
disease and lower height SDS (p = .02) 35. Chi et al did not find an association 
between H. pylori infection and growth failure in their cross-sectional study from 
Taiwan, albeit of high-school children and based again on height SDS rather than 
growth velocity 36. An Australian cross-sectional study of refugee children from 
Africa also failed to find an association between H. pylori infection and subnormal 
anthropometric measurements 37.
A series of cross-sectional studies from Latin America did not find significant evi-
dence linking H. pylori infection and anemia 38. Children with a positive UBT in Cuba, 
Argentina, Bolivia, and Venezuela did not have a statistically increased risk of as-
sociated anemia in comparison with their UBT negative counterparts. In a study 
among Arab-Israeli children, a population with a high prevalence of both H. pylori 
infection and anemia, Muhsen et al only found a statistically significant associati-
on between low ferritin levels and positive H. pylori serology in children less than 
5 years of age but not among older age groups 39. Unfortunately, it remains difficult 
to extrapolate a causal inference from studies of such design.
Idiopathic Thrombocytopenic Purpura (ITP) and Platelet Dysfunction
A multi-center randomized controlled trial of H. pylori eradication in children with 
chronic ITP failed to show an effect of H. pylori eradication on platelet recovery 40. 
Ferrara et al reported a positive effect of H. pylori eradication on the outcome of 
children with chronic ITP with a positive stool antigen test, although their study 
was not a randomized controlled trial 41. One translational study described platelet 




Drug resistance is a growing problem in adults as well as in children. Kato and 
Fujimura studied 61 strains from Japanese children 4–18 years old from 1999–2007 
and reported high primary resistance of clarithromycin (36.1%) and metronidazole 
(14.8%) with consequences for the eradication rate 42. Double resistance was 
detected in 6.6% of the strains. In Bulgaria, resistance to clarithromycin and 
metronidazole was 19% and 16.2%, respectively; multidrug resistance was 1% 43. 
Both authors did not find resistance to amoxicillin and recommend susceptibility 
tests before treatment. Other studies on resistance came from Asia and South 
America; a low clarithromycin resistance rate was found in Malaysia (2.1%), Taiwan 
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H. pylori-positive patients, but in only 38.1% of 404 H. pylori-negative children and 
concluded a positive association. However, the prevalence of H. pylori in the study 
was low, and they did not address CagA status in H. pylori-positive patients in the 
study. On the other hand, researchers in Turkey did not found a positive association 
between H. pylori infection and the severity of esophagitis 28.
DIAGNOSIS
Guarner et al published a ten-year review on diagnostic tests in children between 
1999 and 2009, concluding that most commercial noninvasive tests now have 
adequate sensitivity and specificity for detecting the presence of H. pylori. They 
again emphasized that endoscopy with histopathology is the only method that can 
diagnose and confirm H. pylori infection, its lesions and other causes of symptoms; 
UBT test and monoclonal stool antigen test being good tests for post-treatment 
control 29.
The same rapid office-based stool test using an immunoassay with monoclonal 
antibodies was tested in young children in Germany and in France. Prell et al 
compared it to biopsy tests considered as reference in the setting of pre-and 
post eradication of H. pylori and found a sensitivity of 85.5–90.8% and a specificity 
of 91.0–97.6% [30]. Results of Kalach et al. were similar, showing a sensitivity of 87.5% 
and a specificity of 97.8% 31. She et al confirmed the lack of clinical utility of serology 
testing in children and adults, including an unacceptably low IgM sensitivity of 
just 6.8% 32.
EXTRA-INTESTINAL MANIFESTATIONS
Iron Deficiency and Growth
The link between H. pylori infection and anemia or sub-optimal growth remains 
tenuous. Ferrara et al presented retrospective data on a heterogeneous group 
of 102 Italian children aged between 10 and 12 years with iron deficiency anemia, 
suggesting that children with both H. pylori infection (positive stool antigen test) 
and iron deficiency anemia were more likely to have a reduced height standard 
deviation score (SDS) in comparison with children with other causes of anemia 33. 
However, the data spanning an 8- year period lacked growth velocity assessments, 
case-matched controls, and details regarding the etiological work-up. A cross-
sectional study of children from a low socio-economic background from Mexico 
found an association between H. pylori infection and reduced height compared 
to uninfected matched controls and suggested that the risk was cumulative per 
annum above the age of 7 years 34. In a contrasting study from Turkey, Gulcan et 
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of Lactobacillus GG (n = 44) or placebo (n = 39) 53. Subjects were recruited over a 
40-month period, and complete data were only available in 34 of 44 children in 
the probiotic group and 32 of 39 children in the placebo group. No statistically 
significant benefit of probiotic supplementation over placebo was evident in terms 
of either eradication (69% versus 68%) or side effects. There was a no significant 
trend toward less regimen-associated diarrhea in probiotic treated children (6% 
versus 20%), although the study may have been underpowered to detect such 
differences with significance. In a study using functional food to deliver probiotics 
(cheese containing Lactobacillus gasseri OLL2716), Boonyaritichaikij et al studied the 
effects of probiotic supplementation in two groups of asymptomatic kindergarten 
children in Thailand – with or without H. pylori as determined by stool antigen 
testing (n = 132 and 308, respectively) 54. The eradication arm of the study was single-
blinded and nonrandomized, whereas the prevention arm was randomized and 
stratified for age and gender. Compliance was evaluated by the children’s teachers. 
No statistically significant difference was detected between placebo and probiotic 
treatments in either the eradication or prevention arm of the study.
RE-INFECTION AND SPONTANEOUS BACTERIAL CLEARANCE
The extent of spontaneous clearance of H. pylori infection in childhood remains 
unclear. The Pasitos cohort study was established in 1998 to prospectively study 
H. pylori infection in Hispanic children 55. A recent follow-up report from this study 
examined the effect of incidental antibiotic exposure on subsequent H. pylori 
clearance, based on 13C-UBT changes and parental documentation of medication 
exposure 56. Medication dose and duration were not recorded. A remarkable 
78% of 218 children with a previously positive UBT subsequently tested negative, 
especially those between ages 1–3. Of the 205 children with complete medication 
exposure data, 36% received at least one antibiotic course following the initial 
positive UBT, while 68% had a subsequent negative UBT. Notwithstanding the 
number of significant limitations of this study, incidental antibiotic exposure in this 
study cohort seemed to account for a relatively limited proportion of ‘spontaneous 
clearance’ of H. pylori infection.
VACCINATION
A recent editorial questioned the benefit of eliminating H. pylori, as only 10–15% 
of hosts develop ulcerations and only 1% gastric adenocarcinoma. Vaccination 
can not yet be recommended, as our understanding of the bacterium is too 
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(10.6%), and Colombia (3.8%), in notable contrast to the high rates of metronidazole 
resistance in those countries 44–46. In children from Thailand, clarithromycin 
resistance was 29.2% 47. Raymond et al determined antimicrobial susceptibility in 
530 biopsies between 2004 and 2007 by E-test and molecular methods 48. Twenty-
six percent of strains were resistant to clarithromycin, 61% to metronidazole and 
13% to ciprofloxacin in adults; in an earlier study, they reported primary resistance 
of 22.8% for clarithromycin in children through a one-year period. All authors 
recommend periodic monitoring of antibiotic susceptibility to tailor treatment and 
prevent eradication failure.
Sequential Therapy
Pediatric trials of sequential therapy (ST) for H. pylori eradication have previously 
reported a superior efficacy over conventional therapies (CT) 49,50. Two recent 
meta-analyses of sequential therapy trials in adults and children suggested a 
benefit of a sequential therapy eradication regimen over conventional 7- or 10-day 
eradication regimens. Tong et al included 11 randomized controlled trials published 
up to February 2008 that compared ST to CT, including three pediatric studies 51. 
The reported pooled risk ratios for eradication suggested superiority of ST over CT 
for both 7 -day and 10 -day regimens (1.23, CI 1.19–1.27 and 1.16, CI 1.1– 1.23, respectively). 
The frequency of adverse effects of therapy was similar between the groups. Gatta 
et al included studies published up to October 2008 in their meta-analysis and again 
suggested a benefit of ST over CT, with an odds ratio for eradication of 1.98 (95% CI: 
0.96–4.07) in the pediatric trials 52. While publication bias is an unlikely explanation 
of the findings, a number of over-riding concerns remain concerning the use of ST 
based on these analyses to date. The quality of the studies included was variable, 
and almost all were conducted in Italy. In addition, the number of patients in the 
individual trials has been relatively small and compliance concerns regarding a 
regimen that involves changing medications at the mid-point persist. Whether the 
medications in the ST regimen would be as effective if given ‘conventionally’ rather 
than sequentially is also unclear. These questions remain to be answered by well-
designed, multi-center, high-quality studies in different geographic regions before 
ST is adopted as the new ‘first line’ eradication regimen for children.
Probiotic Therapy
A lack of benefit of probiotic administration on H. pylori eradication in children 
was reported in two studies this year. In a randomized, double-blind placebo-
controlled trial, Szajewska et al randomized children receiving 7 days of triple 
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INTRODUCTION
Helicobacter pylori (Hp) infection is acquired early in life within families 1, 3 and is 
recognized as a causative agent of gastritis, ulcer disease, gastric carcinoma and 
mucosa-associated lymphoid tissue-lymphoma 2. In industrialized countries the 
prevalence of the infection is much lower than in developing countries and the 
rate of infection is related to factors such as ethnic origin. The Netherlands form 
a multicultural community: in 1997 1,063,987 inhabitants belonged to ethnical 
minorities; 279,958 of which originated from Turkey, 232,991 from Morocco and 
287,219 from Suriname 4. Data from Dutch adults show a prevalence of H. pylori 
infection of 33% to 50% 5, 6. In Turkish immigrants with reflux-esophagitis the 
prevalence of Helicobacter pylori infection is as high as 61% (vs. 33% in Dutch adults 
with reflux-esophagitis) 7. 
As there are no data on the frequency of H. pylori infection in young infants in the 
Netherlands, the objective of this study was to investigate its prevalence in this 
group of children. 
METHODS
We determined the titers of IgG antibodies against H. pylori (H. pylori-IgG) in serum 
from 1258 children who were 2-4 years of age born in the Netherlands. The sera 
came from a serum bank built up during a screening study on celiac disease in 1998. 
This study pertained to 6127 children from the general population, who attended 
the community child healthcare centers in the Dutch province of Zuid-Holland8. 
The healthcare centers are attended regularly by 98% of all children born in this 
area. The parents gave informed consent to store the sera of their children at -20° 
C to be used anonymously for research purposes. We selected the sera from all the 
427 children with at least one non-Dutch parent and from the 31 children who, after 
the screening, were diagnosed with celiac disease. In addition, we also analysed 800 
randomly chosen sera from the 5669 children of whom both parents were Dutch 
(computerized selection, SPSS-10 Bijleveld Press, Utrecht, the Netherlands) (Table 1).
Specific IgG antibodies against H. pylori were measured in serum using a validated 
in-house enzyme-linked immunosorbent assay (ELISA) technique9,10. In brief: 
a mixture of six pooled H. pylori strains was sonicated and adjusted to a protein 
concentration of 3 mg/ml. Each well of a microtiter plate (Dynatech Laboratories, 
M129A Chantilly, Virginia, USA) was coated overnight with 100 μl antigen solution (1 
μl suspension/ml) and washed three times with phosphate-buffered saline (pH 7.5) 
containing 0.05% Tween 20. IgG antibodies were measured in serum diluted 1:200, 
by an ELISA technique using peroxidase-labeled conjugates specific for human IgG. 
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ABSTRACT
Aim of the study
To investigate the seroprevalence of Helicobacter pylori infection in young children from the 
general population in the Netherlands.
Methods
Determination of IgG antibodies against H. pylori, using an enzyme-linked immunosorbent 
assay technique (cut-off 0.32 Absorption index (AI), in serum from 1258 children who were 2-4 
years of age. The serum was obtained from a serum bank of 6127 children who attended the 
community child healthcare cnters in the Dutch province of Zuid-Holland. 
Results
In general, we found a seroprevalence of 1.2% of H. pylori infection, with a significant 
difference between the children with parents who were both Dutch (0.5%) and the children 
with at least one non-Dutch parent (2.6%) (p<0.001).
Conclusions
The prevalence of H. pylori infection in young infants in the general population in the 
Netherlands is low. Children with at least one non-Dutch parent form a risk group, however, 
for Helicobacter pylori infection in the Netherlands.
Keywords: Helicobacter pylori, epidemiology, infants, children, 
seroprevalence, the Netherlands.
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The absorbency index was calculated from the mean of two readings of the optical 
density of the serum, corrected for a uniform standard positive serum used in all 
assays. Sera with an absorbency index higher than 0.32 are considered positive for 
IgG antibodies against Helicobacter pylori 9. The sensitivity of the ELISA is 98.5% with 
a specificity of 92% for Hp infection 10. 
The study was approved by the medical ethical committee of the Leiden University 
Medical Center. 
Statistical analysis was based on the two-sample t-test for proportions and on the 
χ2 –square test. For the comparison of prevalence rates with observed proportions 
from earlier studies, the one-sample t-test for proportions was used, using the 
previously observed proportions as null hypothesis.
RESULTS
We found anti-H. pylori-IgG titers higher than 0.32 AI in 15 children, indicating H. 
pylori infection in 1.2% of the children aged 2-4 (Table 1). This frequency is lower 
than the one previously found among Dutch children (Table 2) 12-13. None of the 
children with celiac disease had increased anti-H. pylori-IgG titers in serum.
A significant difference was seen in the frequencies of H. pylori infection in the 
children with two Dutch parents (0.5%) and in those with at least one non-Dutch 
parent (2.6%; p<0.001 Table 1). The non-Dutch parents of all the children with H. 
pylori infection were, one case excepted, not European and in six cases belonged 
to the most common ethnical minorities in the Netherlands: that is, Surinamese, 
Moroccan and Turkish. From the entire group of non-Dutch parents, 58 came from 
Africa, 75 from Asia, 161 from Europe, 10 from North-America, 85 from South-America 
and 38 from the Middle East.
DISCUSSION
To our knowledge this is the first study on the prevalence of H. pylori infection in 
young children in the Netherlands. We found a frequency of H. pylori infection 
lower than the one found in the Netherlands before (Table 2). A possible reason for 
this may be the young age of the children in our study-group, as it is well-known 
that the frequency of H. pylori infection increases with age11. Another possible 
reason for the low frequency of H. pylori infection in our group may be the good 
health status of the children, as they were attending the healthcare centers, which 
are preventive and not curative institutions in the Netherlands. The studies on H. 
pylori infection previously performed in the Netherlands concerned older children 
with health complaints who attended the hospital because of abdominal pain12, 13, 
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Children
 N
Positive Hp-IgG * 
N (%)
Both parents of Dutch origin 800 4 (0,5)
At least one non-Dutch parent 427 11* (2,6)
Countries of origin Suriname 48 1 (2)
Morocco 34 2 (6)
Turkey 31 3 (6)
Germany 17 1 (6)
Ghana 4 1 (25)
Somalia 3 2 (66)
India 2 1 (50)
Other countries 288 0 (0)
Celiac disease 31 0 (0)
Total 1258 15 (1,2)
Table 1. Frequency of positivity of IgG antibodies against H. pylori 
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Table 2. Frequency of H. pylori infection in pediatric populations in the Netherlands
ELISA enzyme-linked immunosorbent assay; EIAG enzyme immuno assay for IgG
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the results of an Italian study of 81 children with celiac disease 21.
We found that the children with at least one non-Dutch parent had a significantly 
higher prevalence of H. pylori infection (2.6%) than the children with two Dutch 
parents (0.5%), (p<0.001). Interestingly, only 1 of these 11 children had European 
non-Dutch parents (Germany, Table 1). Children with parents from Ghana, Somalia 
and India were relatively frequently infected by H. pylori. The number of children in 
this category, however, is small (n = 9) and the results should be interpreted with 
caution. The frequency of H. pylori infection found among the children with parents 
from the three largest ethnical minorities in the Netherlands (i.e. Surinamese, 
Moroccan and Turkish) was 5.3%. This is significantly higher in comparison with the 
frequencies in children from Dutch parents (0.5%) (p<0.001) and in children from 
non-Dutch parents in general (2.6%) (p<0.05). No information is available about the 
prevalence of H. pylori infection in Morocco, Somalia, Suriname and Ghana, but it 
is assumed to be high. The seroprevalence of H. pylori in 346 children from eastern 
Turkey was 44% with a corresponding one of 85% in their mothers and 76% in the 
fathers22. 
In conclusion, we have found that the frequency of H. pylori infection among 
young children in the Netherlands in general is low, but that it is significantly 
higher among Dutch children from the ethnical minorities. In developed countries 
the prevalence of Hp infection is rapidly decreasing mainly due to better socio-
economic conditions, but in developing countries the incidence of infection still is 
very high. Our results indicate that immigration to Europe from countries with high 
rates of H. pylori infection induces the existence of a group of children with high 
risk for H. pylori infection. Pediatricians should be aware of this fact, as H. pylori-
pathology may be particularly frequent among these children who will benefit 
from early diagnosis and treatment.
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surgery12 or suspected viral infections14. In addition, as shown by Roosendaal et al 14, 
H. pylori infection rates in Dutch children have continuously declined over the last 
decades, demonstrating a persistent birth cohort effect. This decline will result in a 
very low prevalence of H. pylori infection in the Dutch population during the next 
few years. One question is whether our population is representative for the general 
Dutch population of 2-4 years of age. Possibly, this is not the case, since we selected 
the sera from all the children with non-Dutch parents and from all the children 
with celiac disease. On the other hand, the total study group is big enough to be 
considered representative for our region. Moreover, the results of our study (1.2% 
H. pylori infection) may represent an underestimation of the true prevalence of H. 
pylori infection, because we used the determination of serum antibodies against 
H. pylori to identify the infection. Although our technique was a home made ELISA 
with a well-known high sensitivity and specificity for H. pylori infection in adults, 
the sensitivity of serological tests may be lower in children under the age of six 11. 
On the other hand, our home made Elisa contains the extract of 6 H. pylori strains 10 
, which improves the sensitivity and specificity and to cover infrequent strains of H. 
pylori. In addition, our home made ELISA has already been used in two other studies 
in children 15, 16, showing that the increase in sensitivity with age is not significant. 
A recent collaborative European study using the kit Pyloritest EIA-G III (Orion 
Diagnostics, Espoo, Finland), also with a cut-off of 0.32 AI, has shown that serology 
can have excellent performance among children17, but the authors observed a 
trend in better performance with increasing age or with lowering the cut-off. If we 
assume a lower cut-off of positivity for our young children (usually 30% lower than 
the cut-off for adults for other ELISA tests), in our group there were only 39 children 
with a cut-off higher than 0.20 AI, giving a frequency of positivity of 3%, which still 
is very low.
The golden standard to assess H. pylori infection in children remains upper 
gastrointestinal endoscopy with biopsies2, 23, but this invasive method is not 
acceptable for epidemiological studies. Nowadays, stool and breath tests can be 
used in epidemiological studies on H. pylori infection 11, 18, but till now these tests 
have not been validated in young children as those in our study. The availability of 
a serum bank from a large population of young healthy Dutch children offered us 
a unique opportunity to perform this study, even if we assume a certain degree of 
false negative results from serology in children younger than 5 years19. In addition, 
serology is a well-accepted non-invasive test to perform epidemiological studies20 
and it allowed us to compare the results in our population with those found in the 
other Dutch pediatric studies, which also used serological techniques (Table 2).
We found no positive anti-H. pylori-IgG among the sera from the children with 
celiac disease identified by the mass screening study 8, which is in agreement with 
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15.   Sierra R, Munoz N, Pena AS, Biemond I, van Duijn W, Lamers CB, Teuchmann S, Hernandez 
S, Correa P. Antibodies to Helicobacter pylori and pepsinogen levels in children from Costa 
Rica: comparison of two areas with different risks for stomach cancer. Cancer Epidemiol 
Biomarkers Prev 1992;1:449-54.
16.   Vollaard AM, Verspaget HW, Ali S, Visser LG, Veenendaal RA, Van Asten HA, Widjaja 
S, Surjadi Ch, Van Dissel JT. Helicobacter pylori infection and typhoid fever in Jakarta, 
Indonesia. Epidemiol Infect 2006; 134: 163-70.
17.  Megraud F. European Paediatric Task Force on Helicobacter pylori. Comparison of non-
invasive tests to detect Helicobacter pylori infection in children and adolescents: results of a 
multicenter European study. J Pediatr 2005;146:164-7.
18.   Van Doorn OJ, Bosman DK, van’t Hoff BW, Taminiau JA, ten Kate FJ, van der Ende A. 
Helicobacter pylori Stool Antigen test: a reliable non-invasive test for the diagnosis of 
Helicobacter pylori infection in children. Eur J Gastroenterol Hepatol. 2001;13(9):1061-5.
19.   Corvaglia L, Bontems P, Devaster JM, Heimann P, Glupczynski Y, Keppens E, Cadranel 
S. Accuracy of serology and 13C-urea breath test for detection of Helicobacter pylori in 
children. Pediatr Infect Dis J. 1999 Nov;18(11):976-9.
20.   Malaty HM, Nyren O. Epidemiology of Helicobacter pylori infection. Helicobacter 2003;8 
Suppl 1:8-12. 
21.   Luzza, Francesco. Mancuso, Maria . Imeneo, Maria. Mesuraca, Luigi . Contaldo, Antonio. 
Giancotti, Laura . La Vecchia, Anna M. Docimo, Corrado. Pensabene, Licia Strisciuglio, Pietro. 
Pallone, Francesco. Guandalini, Stefano : Helicobacter pylori Infection in Children with 
Celiac Disease: Prevalence and Clinicopathologic Features. J Pediatr Gastroenterol Nutr 1999; 
28:143-6.
22.   Yilmaz E, Dogan Y, Gurgoze MK, Unal S. Seroprevalence of Helicobacter pylori infection 
among children and their parents in eastern Turkey. J Paediatr. Child Health 2002; 38:183-6.
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INTRODUCTION
Not only peptic ulcers, but also erosions, reported in 10–20% of symptomatic 
children infected with Helicobacter pylori undergoing upper endoscopy 1–6 remain 
less frequent than in adults. However, these data originate from monocentric studies 
enrolling a small series of children. In one large prospective European multicenter 
study, aimed at assessing antibiotic resistance of H. pylori strains, including more 
than 1400 symptomatic infected children, gastric, or duodenal ulcers were found 
during endoscopy in 3.5% of children below 6 years of age, in 4.6% children aged 
6–11 years, but in 10.4% of those older than 12 years 7. 
Ulcers or erosions also occur in H. pylori negative children, especially those receiving 
NSAIDs 8. Other known causes of peptic lesions are stress, Crohn’s disease, and 
various exogenous agents 1–4. 
There is a lack of solid data about the frequency of ulcer disease in children and 
the frequency of H. pylori and other etiologic risk factors in children with peptic 
ulcer disease. The European Paediatric Task Force for H. pylori decided to conduct a 
descriptive prospective study in 14 European countries to evaluate in a population of 
children referred for upper gastrointestinal (GI) endoscopy, not only the frequency 
of gastric or duodenal ulcers, but also erosions in relation to H. pylori infection and 
various other risk factors. 
PATIENTS AND METHODS 
Patients
The study was carried out for one month (January - February 2007) in 19 centers in 14 
European countries. In each center, all the children aged below 18 years undergoing 
an upper gastrointestinal endoscopy were enrolled. Parental informed consent 
and child ascent was obtained as requested by local ethical policy in the different 
European countries for the collection of clinical information in an anonymous 
form including the following items: presence of gastric or duodenal ulcers and/
or erosions, age, sex, known chronic disease, and indication for endoscopy. In 
addition, in children with ulcers and/or erosions, macroscopic and microscopic 
findings were collected including the H. pylori status and further information 
on potential risk factors such as medications during the last 4 weeks, ethnic 
background, and education level of the parents. Lifestyle habits including smoking 
and alcohol consumption were also collected. The Ethics Committee of Queen 
Fabiola Children’s University Hospital, Brussels, Belgium approved the protocol for 
anonymous data collection and analysis. 
H. pylori status was determined in patients exhibiting gastric and or duodenal 
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ABSTRACT
There are no solid figures of the frequency of ulcer disease during childhood in Europe. We 
assessed its frequency and analyzed known risk factors. 
Patients and methods 
Ulcers, erosions, indications, and risk factors were recorded in all children undergoing an 
upper gastrointestinal endoscopy in a prospective study carried out during one month 
simultaneously in 19 centers of 14 European countries.
Results 
Ulcers and/or erosions were observed in 56 out of 694 children. Children with ulcers/
erosions were significantly older than those without lesions (10.3±5.5 vs. 8.1± 5.7 years, P = 
0.002). Helicobacter pylori infection was present in 15 of 56 children (27%); NSAIDs were used 
in eight, steroids in five, immune-suppressive drugs in five, antibiotics in six, antacids in one, 
H2-blockers in six and proton pump inhibitors in eight children (more than one risk factor 
was detected in 32 of 56 children). No risk factors were observed in 24 of 56 children (43%). 
The main indications for endoscopy were epigastric or abdominal pain (24%) and suspicion 
of gastroesophageal reflux disease (15%). Similarly, epigastric tenderness, hematemesis, 
melena, and weight stagnation were significantly associated with ulcers/erosions, whereas 
sex, H. pylori infection, socioeconomic status and lifestyle factors were equally distributed.
Conclusion 
Although limited by the short-time duration and the heterogeneity of the patients included 
throughout the 19 centers, our study shows a frequency of 8.1% of ulcers and/or erosions in 
children, occurring mainly in the second decade of life. H. pylori infection and gastrotoxic 
medications were less frequently implicated than expected.
Keywords: child, erosion, ulcer, Helicobacter pylori
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ulcers but also erosions according to various diagnostic methods as already 
defined by our conference consensus 9: histology according to the updated Sydney 
classification 10, culture, rapid urease test, 13C urea breath test, and stool antigen. 
H. pylori infection was confirmed when culture or at least two diagnostic tests were 
positive. The H. pylori status was considered as not valid, that is, false negative result, 
when children received antibiotics, proton pump inhibitors (PPI’s), H2 -blockers or 
antacids within 4 weeks before endoscopy. 
To limit interindividual interpretation of endoscopic findings between observers in 
the different centers, a clear description and definition of ulcers and erosions was 
adopted by consensus according to the minimal standard terminology for digestive 
endoscopy: ulcer was defined as a deep defect in the mucosa with an inflamed 
edge; erosion was defined as a small (<3mm) superficial defect in the mucosa, of 
white or yellow color 11. Endoscopic bleeding signs were noted according to the 
Forrest et al 12 classification into six classes: IA arterial spurting bleeding, IB arterial 
oozing bleeding, IIA visible vessel, IIB sentinel clot, IIC hematin covered flat spot, 
and no stigmata of hemorrhage.
Ulcers and/or erosions were also subclassified as secondary, when children showed 
H. pylori infection, received either NSAIDs or steroids during the four weeks prece-
ding endoscopy, or presented with a known chronic disease, that is, inflammatory 
bowel syndrome (IBD), polyarthritis, and other rheumatic diseases. Primary lesions 
were those without an identified etiology.
Statistical Analysis
Calculation of mean, median, standard deviation, and range of all quantitative 
parameters, descriptive analysis of repartition for qualitative parameters, 
performance of the χ2 test or Fisher’s exact test when appropriate and the 
monovariate analysis were done using the Stat-View System (Abacus, California, 
USA), whereas the multivariate analysis was done using the STATA 7.0 System (Stata 
Inc., California, USA). All tests performed were two-tailed, with P value less than 0.05 
considered significant. 
Frequency of gastric and/or duodenal ulcer/erosion was analyzed in the study 
cohort, and their clinical signs and additional descriptive data. Frequencies of 
risk factors in the group of children with gastric and/or duodenal ulcer/ erosion 
compared with those without lesions were precise with 95% confidence interval. 
The risk factors considered are sex, age as a variable divided into two age groups (<10 
and >10 years), indications of endoscopy, and known chronic disease. Risk factors 
were first analyzed using monovariate analysis, then logistic regression analyses 
using a backward stepwise procedure to adjust for every variable. Only variables 
exhibiting a P value less than 0.2 by the monovariate analysis were analyzed by 
Chapter 5
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H. pylori status  
Positive 0 0 6 9
Negative 11 10 7 10
Not tested 0 3 0 0
H. pylori status  
Valid 9 9 9 11
Not valid* 2 4 4 8
Known chronic diseases  
IBD 0 0 3 4
Polyarthritis or other rheumatic diseases 0 0 0 2
Chronic neurologic disease 1 2 0 1
Chronic lung disease 0 0 1 0
Chronic liver disease 0 1 0 2
Food allergy 0 0 0 1
Other allergic disease (except food allergy) 0 0 0 1
Oncology (during chemotherapy) 1 0 0 0
Celiac disease 1 1 0 0
Others 2 0 2 0
Absence of known chronic disease 6 9 7 8
Drug consumptions  
None 5 7 6 9
Yes 6 6 7 10
NSAIDs 0 0 5 3
PPIs 0 3 0 5
H2 blockers 2 1 2 1
Antacids 0 0 1 0
Antibiotics 0 0 3 3
Steroids 0 0 1 4
Immuno-suppressive drugs 0 0 1 4
*  H. pylori status not valid, i.e. due to the use of either antibiotics, or PPIs or H2 blockers 
during the 4 weeks preceding endoscopy  
IBD: inflammatory bowel disease; PPIs: protonpump inhibitors; NSAIDs: non-steroidal 
anti-inflammatory drugs
Table 2 Primary and secondary ulcers and/or erosions characteristics
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the multivariate logistic model. Results were expressed as odds ratios (ORs) with 
95% confidence intervals. Statistical significance was set up at the P value less than 
0.005, and all P values were two-tailed. 
RESULTS
Frequency and description of ulcers and/or erosions 
A total of 694 children were enrolled, 349 female and 345 male, median age 8.2 years 
(range 1 month–18 years), unevenly distributed between the different centers.
Ulcers and/or erosions were observed in 56 of 694 children (8.1%), with a wide 
variation (0–22%) in the 19 European centers (Table 1). In each and all centers, 
children with ulcers and/or erosions were significantly older than those without 
lesions (10.26±5.5 vs. 8.11± 5.7 years, P=0.002).
Endoscopic lesions were reported as gastric ulcers in seventeen and duodenal 
ulcers in seven, gastric erosions in 31, and duodenal erosions in 15 children. Most 
of the gastric lesions were located in the antrum (44/48) and the majority of the 
duodenal lesions were located in the bulb (15/22). Duodenal erosions in nine, 
duodenal erosions and ulcer in two, duodenal erosions and gastric ulcers in one, 
duodenal ulcers in five, gastric erosions in 21, gastric and duodenal erosions in two, 
gastric and duodenal erosions and gastric ulcers in one, gastric erosions and ulcers 
in seven, and finally gastric ulcers in eight. Endoscopic bleeding signs were present 
in nine of 56 children (16%). No age difference was observed between children with 
gastric compared with those with duodenal lesions. Among the 56 children with 
peptic ulcers and/or erosions, 24 lesions (11 ulcers and 13 erosions) were classified as 
primary and 32 (13 ulcers and 19 erosions) as secondary (Table 2). 
H. pylori infection was present in 15 of 56 children (27%). These H. pylori infected 
children showed gastric erosions in five, duodenal erosions in three, combined 
gastric and duodenal erosions in one, combined gastric erosions and ulcers in 
four, gastric ulcers in one, and duodenal ulcers were found in one. No significant 
relationship could be found between H. pylori infection and the type of peptic 
lesions. H. pylori status was considered as not valid in six of 24 (25%) and 12 of 32 
(37.5%) patients of the primary and secondary lesions (Table 2).
Gastro–duodenal ulcers versus erosions 
The risk factors in children with ulcers were compared with those with erosions 
and did not show any statistically significant difference: age more than 10 years 
14 of 24 (58.3%) versus 19 of 32 (59.4%), female sex ratio 13 of 24 (54.1%) versus 15 
of 32 (46.8%), H. pylori infection six of 24 (25%) versus six of 32 (18.7%), previous intake 
of medication 13 of 24 (54.1%) versus 16 of 32 (50%) recurrent abdominal pain and 
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of gastroesophageal reflux disease (Table 4). Epigastric pain, hematemesis, melena, 
and weight stagnation were significantly found as the main indication of endoscopy 
in patients with ulcers and/or erosions as compared with those who lacked lesions 
(Table 4).
H. pylori infection was detected in only 15 children (27%) using different diagnostic 
methods: culture in 11, histology in 11, rapid urease test in 4, 13C urea breath 
test in three, and stool antigen test in two. In three children, histology failed to 
detect H. pylori, whereas culture was positive. H. pylori infection may, however, be 
underestimated as H. pylori status was considered as not valid in six of 24 (25%) and 
12 of 32 (37.5%) patients with primary and secondary lesions and in three children 
H. pylori status was not assessed (Table 2). In three children (5.3%), H. pylori was 
eradicated earlier. 
Other complementary data concerned previous H. pylori eradication in three 
children (5.3%). Thirty children were born in Western Europe (53.5%), 24 in Eastern 
Europe (43%), and two in Africa (3.5%); 20 mothers were born in Western Europe 
(35.7%), 22 in Eastern Europe (39.2%), 10 in Africa (17.8%), two in the Middle East, one 
in Asia, and one in North America. 
The educational level of mothers and fathers, according to the number of schooling 
years, was unevenly distributed: less than 9 years for thirteen mothers and nine 
fathers, respectively, 9–11 years for 6 mothers and 13 fathers, more than 12 years for 
23 mothers and 16 fathers, and university degree for six mothers and ten fathers; 
the educational level was not known in eight couples of parents. 
A median of four members of the family were living in the house (range 2 -9), and 
36 children (64%) slept in a personal bedroom.
A history of peptic ulcer in a first-degree family member was reported in six children 
(10.7%). A history of use of medication within four weeks before endoscopy was 
reported in 29 children (51.7%); some children were taking more than one drug: 
NSAIDs in eight (14.3%) where five of 13 and three of 19 in the secondary ulcers 
and/or erosions and erosions only groups, respectively, antacids in one (1.7%), H2-
blockers in six (10.7%) where three of 24 (two ulcers and/or erosions, one erosions 
only) and three of 32 (two ulcers and/or erosions, one erosions only) in the primary 
and secondary lesions groups, respectively, PPIs in eight (14.3%) where three of 
24 (three erosions only) in the primary and five of 32 (five erosions only) in the 
secondary lesions groups, antibiotics in six (10.7%) where three of 13 (three ulcers 
and/or erosions) and three of 19 (three erosions only) in the secondary lesions 
groups, steroids in five (8.9%) where one of 13 (one ulcer and/or erosion) and four 
of 19 (four erosions only) in the secondary lesions groups, and immuno-suppressive 
drugs in five (8.9%) where one of 13 (one ulcer and/or erosion) and four of 19 (four 
erosions only) in the secondary lesions groups (Table 2). In addition, a history of 
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epigastric pain as main symptoms 17 of 24 (70.8%) versus 16 of 32 (50%), known 
chronic diseases 10 of 24 (41.6%) versus 18 of 32 (56.3%). In three children with 
gastro–duodenal erosions H. pylori status was not assessed.
Complementary data 
The median age of the 56 children presenting with ulcers or erosions was 11.38 years 
(range 0.16–17.8) with a sex ratio of 1. Known chronic diseases were reported in 321 
of 694 children (Table 3), which were significantly higher in patients with ulcers and/
or erosions as compared with those without lesions. Seven of 32 children presented 
with IBD and two of 32 with polyarthritis, or other rheumatic diseases (Tables 2 and 
3). Main indications for endoscopy were epigastric or abdominal pain and suspicion 
Table 3 Known chronic diseases in all enrolled patients
CI : confidence interval ; IBD : inflammatory bowel disease ; 
NS: not significant ; OR : Odds ratio
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OR 95% CI P value
Chronic neurologic disease 34 (5.3) 4 (7.1) 38 1.5 0.5 - 4.2 NS
Chronic cardiac disease 4 (0.6) 0 4 1.3 0.1 - 23.3 NS
Chronic lung disease 22 (3.4) 1 (1.7) 23 0.7 0.1 - 3.9 NS
Chronic liver disease 31 (4.8) 2 (3.5) 33 0.9 0.2 - 3.3 NS
Chronic renal disease 4 (0.6) 0 4 1.3 0.1 - 23.3 NS
Food allergy (FA) 12 (1.8) 1 (1.7) 13 1.3 0.2 - 7.6 NS
Other allergic disease (except FA) 18 (2.8) 1 (1.7) 19 0.9 0.2 - 5.0 NS
IBD 40 (6.3) 7 (12.5) 47 2.2 1.0 - 5.2 0.05
Celiac disease 37 (5.7) 2 (3.5) 39 0.7 0.2 - 7.8 NS
Polyarthitis or other rheumatic diseases 5 (0.7) 2 (3.5) 7 5.3 1.2 - 24.1 0.04
Clotting disorders 4 (0.6) 0 4 1.3 0.1 - 23.3 NS
Prematurity 8 (1.2) 0 8 0.7 0.1 - 11.6 NS
Post-Transplant 4 (0.6) 1 (1.7) 5 3.8 0.6 - 24.8 NS
Oncology (during chemotherapy) 4 (0.6) 1 (1.7) 5 3.8 0.6 - 24.8 NS
Others 68 (10.6) 4 (7.1) 72 0.7 0.3 - 1.9 NS
Absence of known chronic disease 343 (53.7) 30 (53.57) 373 1.0 0.6 - 1.7 NS
Total 638 56 694    
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alcohol consumption was reported in seven (12.5%) and tobacco smoking in three 
children (5.4%).
Risk factors
Ulcers and/or erosions were more frequently reported in three centers located in 
Belgium, Italy and Turkey (Table 1). In all enrolled children, the analysis of gastro–
duodenal ulcers and/or erosions showed the same risk factor results when analyzed 
separately and as conjointly that epigastric pain, hematemesis, melena, and weight 
stagnation were reported as the most significant clinical symptoms considered 
as risk factors for erosions or ulcers (Table 4). Known chronic diseases such as IBD, 
polyarthritis, or other rheumatic diseases were also considered significant risk 
factors (Table 3).
Children aged above 10 years represented another significant risk factor. Adjust-
Adjusted ORa 95% CI P value*
Results of the multivariate analysis were 
adjusted according to the investigator centers
Age (vs <10 yrs)
> 10 yrs 1.6 0,7-3,6 0,28
Indication of endoscopy (vs. all other indications)b 
Suspected or established gastroesophageal reflux 0.4 0.1-1.2 0.08
Epigastric pain 2.9 1.0-8.2 0.05
Pain awaking child at night 4.4 1.2-16.7 0.03
Hematemesis 12.7 3.0-53.2 0.001
Melena 6.6 1.4-31.9 0.02
Weight stagnation 3.6 1.3-10.2 0.015
Known chronic diseases (vs. all other relevant)
IBD 2.1 0.8-5.7 0.13
Polyarthritis or other rheumatic diseases 6.7 0.5-84.3 0.14
CI: confidence index; IBD: inflammatory bowel disease; OD: Odds ratio
a Odds ratio adjusted on all the variables of the model
* P value obtained by a multivariate logistic model
b  only variables exhibited a P value <0.20 by the monovariate analysis were analyzed by 
multivariate logistic model
Table 5 Multivariate analysis of children with gastroduodenal ulcers and/or erosions
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n (%) n (%) n OR 95% CI P value
Suspected gastroesophageal 
reflux disease
87 (13.6) 3 (5.3) 90 0.4 0.14-1.25 NS
Established gastroesophageal 
reflux disease
66 (10.3) 1 (1.7) 67 0.2 0.1-1.2 0.05
Abdominal distress/pain 92 (14.4) 11 (19.6) 103 1.5 0.7-2.9 NS
Epigastric pain 51 (7.9) 9 (16.1) 60 2.3 1.1-4.8 0.03
Pain awaking child at night 23 (3.6) 4 (7.1) 27 2.2 0.8-6.4 NS
Heartburn 5 (0.7) 0 5 1.0 0.1-18.7 NS
Nausea 2 (0.3) 0 2 2.6 0.1-47.5 NS
Vomiting 16 (2.5) 0 16 0.3 0.1-5.6 NS
Halitosis (foul smelling breath) 1 (0.01) 0 1 3.8 0.2-92.7 NS
Hematemesis 8 (1.2) 5 (8.9) 13 7.9 2.6-24.1 0.00005
Melena 9 (1.3) 3 (5.3) 12 4.3 1.2-15.3 0.03
Weight stagnation 32 (5.0) 7 (12.5) 39 2.8 1.2-6.6 0.02
Chronic diarrhea 20 (3.1) 1 (1.7) 21 0.8 0.2-4.4 NS
Anemia 7 (1.1) 0 7 0.8 0.1-13.3 NS
Iron deficiency 2 (0.3) 0 2 2.3 0.1-47.5 NS
Anorexia 5 (0.7) 0 5 1.0 0.1-18.7 NS
Malaise 11 (1.7) 1 (1.7) 12 1.5 0.3-8.3 NS
G-Tube 22 (3.4) 1 (1.7) 23 0.7 0.1-4.0 NS
Foreign body 4 (0.6) 0 4 1.3 0.1-23.3 NS
Suspected caustic ingestion 9 (1.4) 1 (1.7) 10 0.9 0.2-5.3 NS
Work-up for celiac disease 60 (9.4) 0 60 0.1 0-1.3 0.02
Work-up for IBD 34 (5.3) 6 (10.7) 40 2.3 0.9-5.5 NS
Work-up for portal  
hypertension
34 (5.3) 2 (3.5) 36 0.8 0.2-3.0 NS
Other 38 (5.9) 1 (1.7) 39 0.4 0.1-2.2 NS
Total 638 56 694  
CI: confidence interval; IBD: inflammatory bowel disease; NS: not significant; OR: Odds ratio
Table 4 Indications of endoscopy in all enrolled patients
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of studies published during the last 10 years including a total of 16 080 patients, 
showed that H. pylori was found in 81% of duodenal ulcers, but a lower frequency of 
77% was reported when only the last 5 years were considered15. Associations with 
H. pylori-negative duodenal ulcer were mainly because of false negative results of 
diagnostic methods and the use of NSAIDs 15. This important puzzling observation 
needs a confirmation by a study on a wider scale taking into consideration a longer 
period of time extending necessarily over several seasons. Even more important is 
the correlation to the prevalence of H. pylori infection in each specific geographic 
area as stressed by a recent Israeli paper 6 describing a high incidence of ulcers in 
their Israeli Arab or Russian immigrant children and also as observed, in this study, 
in three European centers of Belgium, Italy, and Turkey (Table 1). 
A much lower frequency of ulcers and erosions (2%) is reported in earlier papers 3, 5 
without reference to age, although with a higher frequency of H. pylori associated 
ulcers and the same trend is reported in the PEDS-CORI database 16. In contrast, 
ulcers were detected in 80 of 1180 H. pylori-positive children (6.8%) in a prospective 
European multicenter study 7.
Our results confirm data published earlier stressing the fact that the age of the 
children is an important risk factor: OR of 3.1 in children older than 11 years 7 and OR 
of 2.1 in this study in children older than 10 years. However, we did not observe the 
age difference between children with gastric ulcer reported 3 to be younger than 
those with duodenal ulcer (6.5 vs. 10.5 years).
Several investigators have suggested that night-time pain associated with nocturnal 
awakening, fasting pain relieved by food intake, pain associated with meals or 
postprandial bitter taste, heartburn and epigastric pain are clinical signs that help 
to distinguish ulcer-positive from ulcer-negative children, although positive for H. 
pylori infection 2. However, in contrast, these clinical symptoms are not found to 
be specific by Roma et al 3, as no significant difference was found with regard to 
clinical symptoms between children with and without ulcer. In this study, the main 
indications for endoscopy were epigastric or abdominal pain (24%) and suspicion 
of gastroesophageal reflux disease (15%). Hematemesis, melena, epigastric 
tenderness, and weight stagnation can be considered as significant risk factors for 
erosions or ulcers alike. 
Together with H. pylori infection, the use of NSAIDs is considered as an important 
risk factor not only for gastrointestinal mucosal injuries in adults, but also in child-
ren 17. In adults, both H. pylori infection and the use of NSAIDs independently and 
significantly increase the risk of peptic ulcer and upper gastrointestinal bleeding 
(UGIB) 18. In children, few studies address the relationship between NSAIDs intake, 
H. pylori infection, and other risk factors inducing mucosal injuries and UGIB.
In a retrospective review of the medical records of 112 Taiwanese children who 
Gastric and duodenal ulcers in Europe
ment of the multivariate analysis according to the centers showed that the same 
risk factors were as significant and that pain-awaking at night also reached a level 
of significance (Table 5).
Finally, no significant relationship could be shown between H. pylori infection and 
the type of peptic lesions. As H. pylori status was not systematically determined in 
children without ulcers and/or erosions, thus an OR could not be determined for 
children with or without ulcers/erosions.
DISCUSSION
In this prospective European study, the frequency of ulcers or erosions in children 
referred for upper endoscopy reached the unexpected high figure of 8.1%. This 
frequency is possibly underestimated because of the use of gastro-protective 
drugs including H2 -blockers and PPIs preceding the endoscopic procedure.
An important variation of this frequency was observed among the different centers 
participating in the study (0–22%). This can be because of several factors in the dif-
ferent countries: referral habits, use of gastro-protective drugs before endoscopy, 
interference of adult gastroenterologists taking care of adolescents, and possible 
unknown geographical influences.
Lesions of ulcers or erosions were observed mainly around the second decade of 
life, and children older than 10 years were significantly more at risk for ulcers and ero-
sions alike. Epigastric tenderness, pain-awaking at night, hematemesis, melena, and 
weight stagnation were significant risk factors for lesions of ulcers or erosions alike. 
The fact that H. pylori infection was observed in only 15 of 56 (27%) children in dif-
ferent European centers is in agreement with the decreasing prevalence of H. pylori 
infection in adults observed in Europe 13. The relationship between chronic peptic 
ulcer disease and H. pylori is widely documented in adults, especially in relation 
with duodenal ulcers. A higher rate of H. pylori infection was also described3 in 
children with duodenal ulcers compared with those with gastric ulcers (62 vs. 20%, 
P<0.001). However, in other pediatric papers, H. pylori infection was detected in only 
three of 11 (27%) children with duodenal ulcer 5. Similarly, in an older publication, it 
was reported in six of 11 children with duodenal ulcers (55%) versus two of four with 
gastric ulcers (50%) 14. In this study, we did not find in any of the different European 
countries a significant relationship between H. pylori infection, present in 15 of 56 
children (27%) and the location of the gastric or duodenal ulcers/erosions. Further-
more, the fact that H. pylori status was considered as unreliable because of the use 
of either PPIs, H2 - blockers or antibiotics in the period preceding endoscopy in six of 
24 and 12 of 32 children with primary and secondary lesions, may also influence the 
low frequency of H. pylori infection observed in our series (Table 2). A recent review 
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presented with UGIB, H. pylori infection was present and closely related to 
primary duodenal ulcers in 55% of patients without any other underlying disease, 
contrasting with the lower figure of only 17% in children with several underlying 
diseases19. UGIB is frequently related to drug ingestion with almost 50% of cases 
showing gastric erosions secondary to drug intake 20.
In a recent study based on data of the French Pharmacovigilance system 21 analyzing 
all serious upper gastrointestinal complications such as gastritis, duodenitis and 
esophageal lesions, gastric or duodenal ulcers were reported in 61 children aged 
11 months - 15 years during treatment with niflumic acid, ibuprofen, and tiaprofenic 
acid, associated with NSAIDs in children. This important study concludes that NSAIDs 
used in children for fever or moderate pain are associated with a risk of serious UGIB 
complications that increase with duration, dose, and association with a salicylate.
In our study, medication intake during the last 4 weeks was reported in 29 out of 
56 children with erosions or ulcers (51.7%), but NSAIDs consumption in only eight 
children (14.3%) and steroids in another five (8.9%). The frequency of tobacco (three 
cases, 5.4%) and alcohol (seven cases, 12.5%) consumption is low in the population 
of children with ulcers and/or erosions and does not allow drawing firm conclusions 
about their influence on the pathogenesis of ulcers.
In this study, we found that the frequency of primary gastric and duodenal ulcers 
and/or erosions was slightly lower than those of secondary lesions (24/56 and 32/56), 
lower than the figures of 19 of 36 primary peptic ulcers and 17 of 36 secondary les-
ions published by Drumm et al. 22 20 years ago.
Finally, because the results of this study show, in children, a higher frequency than 
expected of ulcers or erosions, the evaluation of the multiple risk factors for the 
detection or prevention of ulcers and/or erosions needs a prospective case–control 
study over several seasons taking into account the specific prevalence of H. pylori 
infection in each different geographical area. These lesions should be systemati-
cally screened in symptomatic children with epigastric pain, hematemesis, melena, 
or weight stagnation to adapt adequately the subsequent treatment. 
CONCLUSION
In this prospective European multicenter study a frequency of 8.1% of ulcers and/or 
erosions was observed in children mainly around their second decade of life with 
a high variability among different centers. Epigastric tenderness, pain awakening 
the child at night, hematemesis, melena and weight stagnation can be considered 
as significant risk factors for ulcers or erosions indifferently. The unexpectedly 
low frequency of H. pylori infection and NSAID-use in these patients questions its 
etiologic role causing ulcers and/or erosions.
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Helicobacter pylori (Hp) is known to be responsible for chronic gastritis, predisposes 
to gastric and duodenal ulcers, and has been recognized as a type 1 gastric carcin-
ogen in humans by the International Agency for Research on Cancer since 19941. 
In spite of this, only a small part of the infected persons develop gastric cancer, so 
additional factors as virulence genes of the bacterium and life style of the host may 
be involved in progression toward cancer2,3. 
Infection with Hp is ubiquitous with prevalences of 40-50% in adults of developed 
countries and 80-90% in developing countries4. In general initial infection occurs 
during childhood5, while chronic disease predominantly emerges at adolescent or 
adult age. In developing countries, the acquisition of the infection appears to occur 
earlier in life than in developed countries and in the latter a smaller percentage of 
children are infected. The infection prevalence increases with age and is usually 
associated with low socio-economic status (SES), crowding conditions, and poor 
hygiene6-8. Humans are the main source of Hp infection. The routes of transmission 
are unclear, although the presence of Hp in saliva, dental plaque, and stool seems 
compatible with both oro-oral and faecal-oral inter-human transmission9.
Indonesia and Japan reportedly have a similar prevalence of Hp infection in adults, 
but the incidence of gastric cancer in Yogyakarta and Semarang (Indonesia) is 2% 
and 1%, respectively, of that in Japan. Tokudome et al. observed a Hp seroprevalence 
of only 2% both in man and woman in a study in 171 persons of the general 
population in Semarang, Indonesia, significantly lower than the 62% and 57% they 
observed for Japan and suggested that the rarity of gastric cancer in Semarang may 
be attributable to the relatively low prevalence of Hp infection10,11. On the contrary, 
Abdullah et al. observed in dyspeptic patients in Jakarta (Indonesia) and Japan 
similar percentages of Hp infections, but the Japanese patients had a significantly 
higher grade of gastritis and prevalence of mucosal atrophy and intestinal 
metaplasia, both precursors of gastric carcinoma12. A decreasing incidence of Hp 
has been shown in Jakarta from 1998 - 2005 with a stable incidence of intestinal 
metaplasia13. There are recommendations to vaccinate people in developing 
countries with high Hp prevalence to prevent gastric carcinoma, but before such a 
vaccine would be recommended, prevalence rates of Hp infection in different areas 
in those countries are needed14.
Only few data exist on the prevalence of Hp infection in Indonesian children, and 
are either part of prevalence studies on adults that include some older children15, or 
comprise exclusively older children16 with exception of two conference abstracts17,18 
(table 1). Furthermore, most of the studies were based on determination of non-




In Indonesian adults and preschool children the reported prevalence of Helicobacter pylori 
(Hp) infection is considerable high, with rates between 49% and 54%. Data on the prevalence 
in younger children is scarce. We studied the prevalence of Hp in young children across the 
socio-economic classes of Bandung, Indonesia. 
Methods:
Subjects were 150 healthy infants aged 3-24 months, living in the rural area of the Kiaracondong 
subdistrict. The socio-economic status (SES) was assessed according to the salary of the 
father. Stool samples were collected in September 2003 and September 2005 and tested for 
Hp using a monoclonal enzyme immunoassay (IDEIATMHP STAR, Dakocytomation, Denmark). 
Results: 
At first occasion, 4 out of 150 stool samples were Hp positive, giving an overall prevalence 
of 2.7%. All positive samples derived from the two youngest age groups (3-9 months), 
indicating a prevalence of 8% in that specific subgroup. The youngest infected child was 
3 months old. Three of the 4 positive tested children belonged to the lowest SES, while 1 
belonged to the medium status. Two years later, all 112 samples available for follow-up tested 
negative, whereas Hp specific treatment had not been provided. 
Conclusion:
The prevalence of Hp infection in the age group 3-9 months is considerably high (8%) and 
indicates a very early acquisition of the infection. Spontaneous clearance is possible, since 
a follow-up analysis 2 years later revealed negative results for 3 patients tested originally 
positive.
Keywords: Helicobacter pylori; children; stool test; 
monoclonal enzyme immunoassay; Indonesia.
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Table 2. Prevalence of Helicobacter pylori (Hp) in 150 young Indonesian children 
using stool antigen detection with monoclonal HpSA EIA.
*Socioeconomic status Indonesian Government Criteria: salary of the father: 
< 500.000 Rupiah: low; 500.000-1.000.000 Rupiah: Medium; > 1.000.000 Rupiah: high.
General Hospital for processing. The samples were stored at –70°C before being 
shipped in dry ice-cooled boxes to the Netherlands. Within one week after arrival 
at the Laboratory of Medical Microbiology, Leiden University Medical Centre, 
all 150 samples were tested blindly for Hp antigens using a monoclonal enzyme 
immunoassay (IDEIATMHP STAR, Dakocytomation, Denmark) in one run following 
the instructions of the manufacturer.
Twenty-four months later, new stool samples of the same children were collected 
by the same health care nurses. At this occasion a questionnaire was filled out by 
the parents, assisted by the trained health nurse. This questionnaire provided us 
data about living conditions, family size, and the education level of the parents 
and the history of abdominal complaints, gastro intestinal bleeding or carcinoma 
within the family as well as health complaints and medication (antibiotics) of the 
index child. Samples were transported similarly as described above and were again 
tested by the same monoclonal stool-test, blinded, in one run. Samples having 
readings ≥ 0.190 units were considered positive and samples ≤ 0.190 negative. 
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desirable for young children. The aim of our study was to conduct a prevalence study 
of Hp infection in young children living in the crowded rural district of Bandung, 
Indonesia. We also took the opportunity to investigate the same population two 
years later to recognize changes in prevalence rates of Hp infections. 







200017 Mataram 3-7 unknown 49.4 Serology
200018 Surabaya 10-75 unknown 31.2 Serology
200616 Jakarta < 14 51 53 Serology
200515 Jakarta 16-74 63 9.5 Stool
200511 Yogyakarta Adults 91 4(f), 5(m) Serology and 
UBT
200510 Semarang Adults 171 2(m), 4(f) Serology
This study (2003-2005) Bandung 0.3 - 4 150 2.7 Stool 
F: female; M: male; UBT: Urea Breath Test
Table 1. Reported frequency of Hp infection in Indonesia 
METHODS
Study design and population
A longitudinal community-based cohort study was conducted in a peri-urban 
area of Bandung (Kiaracondong subdistrict), on the island of Java, Indonesia. Stool 
samples were collected in September 2003 and September 2005.
In September 2003, 150 healthy children aged less than 2 years of age were enrolled 
for the study. The children were randomly selected from the district population 
across the socio-economic status (SES). The parents of the participating children 
gave informed consent before sampling. The ethics committee of the local Padja-
daran State University (Bandung) approved the design and concept of the study.
Sample collection and stool tests
Fresh stool samples were collected at the children’s homes, by local health nurses. 
The parents (mostly the mothers) were interviewed about their SES and the health 
status of their children. 
The children were divided into 6 age categories of three months each (table 2). 
Stool samples were collected and stored in cooled boxes at -4°C immediately and 
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Table 3.  Prevalence of Hp infection in children in different countries
in South and East-Asia
PCR: Polymerase chain reaction; EIA: enzyme immunoassay; 
UBT: Urea Breath test; IB: immunoblot
RESULTS
In total 150 infants (82 male and 68 female) aged 3-24 months were enrolled (table 
2). The SES was low for 32 (21.4%), medium for 113 (75.3%) and high for 5 (3.3%) of the 
children. 
Four stool samples tested Hp-positive at the first sampling (2 females), resulting in 
an overall Hp-prevalence of 2.7%. All positive samples originated from the groups 
aged 3-6 and 6-9 months, leading to a prevalence of 8% for this subgroup. The 
youngest infected child was aged 3 months and 4 days. Three of the positive 
children belonged to the lowest SES and 1 to the medium SES.
Two years after the first sampling, the Hp status was followed-up. Unfortunately, 
due to a big fire in the subdistrict, 27 children originally tested negative had moved 
elsewhere and attempts to trace their actual addresses remained unsuccessfully. 
In addition, one Hp positive tested child died from pneumonia and 10 Hp negative 
tested children could not be traced, so in total 112 children were available for the 
follow-up study. All samples in the follow-up were Hp-negative, including 3 of the 
children who were previously tested positive. Those 3 children had never been 
treated with antibiotics. None of their parents reported abdominal pain, ulcer or 
gastric carcinoma, nor underwent abdominal surgery.
DISCUSSION
In this longitudinal community-based cohort study we found a prevalence of 2.7% 
Hp infection in healthy Indonesian children of a very young age (<2 years), tested 
by an EIA in stools using an Hp specific monoclonal antibody. This result agrees 
with the previous reported prevalence of Hp infection in that age in some other 
developing countries, but it is not as high as in other countries in South-East Asia 
such as Bangladesh, Pakistan and Malaysian Borneo (table 3). Interestingly, none of 
the 150 children tested positive at the follow-up after 2 years, including 3 children 
who tested Hp positive at the first sampling. One possibility to explain our findings is 
that the stool test used lacks sensitivity and specificity. Gold standard for detection 
of Hp infection in children is upper endoscopy with biopsies for pathology, urease-
test and culture19. However, these invasive tests are not suitable for epidemiologic 
studies in healthy children. The 13C-Urea Breath Test (UBT) is the most appropriate 
non invasive diagnostic tool to diagnose Hp infection and to confirm therapeutic 
successes of eradication. A disadvantage of this UBT is the need of relatively 
expensive analytical equipment. 
Serologic tests are unreliable in young children and have revealed disappointing 




The unexpected negative results in the second sampling could be associated with 
spontaneous clearance of the infection, as it has been previously shown in 42% of 
infected Egyptian children aged 6-17 months after a follow-up of 6 months41. This 
phenomenon has been also observed in 77% of a prospective cohort of Mexican 
children at 24 months of age. Interestingly 19% of the children were infected again 
later42. Transient Hp infection has also been reported in Japanese children followed-
up from birth till 24 months, even if this could also have been the result of false 
positive initial tests (HpSA)43. Another possibility is that Hp infection disappeared 
because of antibiotic therapy for other infectious disorders. However, the parents 
of the children in our cohort, who cleared the Hp infection, did not report any use 
of antibiotics during the follow-up period in their questionnaires.
Most of the children from our study group were breastfed for more than a year. 
It has been suggested that breastfeeding may play a role in preventing the 
acquisition of Hp infection during the first year of life due to passive immunity 
by anti-Hp-antibodies in the milk44. However, contra dictionary results have also 
been published reporting a positive correlation between breastfeeding and Hp 
infection45, and no correlation both in Brazil46 and in Germany47. However these 
studies have the limitation that they were conducted years after the period of 
breastfeeding48,49, or were based on self-reported history. In addition less-sensitive 
serology tests were used in most of these studies 23,34,45-47. 
Strengths and limitations of our study
Our study is the first study of Hp prevalence in young Indonesian children, 
determined by the monoclonal stool test. Although the test has not been validated 
in Indonesian children, it performs well in children of the same age group from 
Bangladesh. Moreover, retesting positive stool samples with a polyclonal stool test 
gave same results.
CONCLUSION
The results of our study demonstrate that the prevalence of Hp infection, detected 
by a monoclonal stool test, is 2.7% in healthy children aged 3-24 months living 
in a crowded subdistrict in Bandung, Indonesia. In the group aged 3-9 months 
the prevalence is 8%. This indicates that very young children already acquire Hp, 
despite the local practice of prolonged breastfeeding. Interestingly (spontaneous) 
clearance of Hp infection was observed. Our study supports the recommendation to 
start very early with infection preventive measures, such as vaccination if available 
in future. More extensive data on the Hp prevalence in the various (sub)populations 
and age groups living in the area are needed to justify such invasive measurements. 
reaction remains positive for months after successful eradication therapy20. 
Therefore, a specific Hp antigen test in stool samples is the preferred non-invasive 
test to use for epidemiological surveys. We applied a monoclonal stool antigen test 
in Indonesian children, that has previously been validated in children in Europe with 
a high sensitivity and specificity (98 and 99% respectively), albeit less sensitivity 
and specificity for younger children21. The performance of this test is significantly 
better than the polyclonal HpSA test 9,22,23. Our stool test has also been validated in 
Egyptian children and demonstrated a good sensitivity (94%), but less specificity 
among children less than 6 years24. In contrast Megraud et al demonstrated that 
UBT, stool antigen and antibody detection in serum and urine in children, showed a 
trend for improved sensitivity with age except for the stool test in comparison with 
biopsy-based tests25. The low specificity of the test applied in our study, prompted 
us to use a second assay (HpSA, Meridian, Bioscience, Europe) on the 4 positive 
tested samples. All positive tested samples remained positive. The Canadian 
Consensus Group on Hp has judged that, in settings where the breath test is not 
available for children, the monoclonal test forms an excellent alternative to assess 
the status of Hp 21,26.
Table 3 summarizes results of the available studies of Hp infection in children in 
different countries in South and East-Asia. Most of the studies used serology or stool 
tests using polyclonal antibodies 15,22,23,27-35,36. Only one study compared serology to 
monoclonal stool test in children of Bangladesh and showed a prevalence of 49% at 
the age of 24 months35. In previous studies from Mataram, Indonesia, the prevalence 
of Hp among kindergarten children (3-7 years) using passive hemagglutination 
(PHA) was 49.9%17. 
In most of the studies the prevalence of Hp infection increases with age, but in our 
study we did not observe this phenomenon. In developing countries with high Hp 
prevalence most of the children become Hp-infected at a very young age. The ab-
sence of Hp infection for 9-24 months old children in our study could be due to the 
small sample size, which is unlikely, especially given the 0% estimate 2 years later, 
the small number of children from low SES included in the older groups or both.
Low Hp-prevalence populations have been described earlier in Java13 and in a 
multiracial population in Malaysia11,32,37-39 as well as in Africa40. Boey and Goh already 
described in Malaysia the phenomenon of a different Hp prevalence between ethnic 
groups in one area for both adults as well as children, the so-called “racial cohort 
phenomenon”: the prevalence of 6% in “Malay”children < 5 years was lower than 
that in “Chinese and Indian” children (7.6 and 10% respectively) living in the same 
area31,32. Possibly such a phenomenon could be responsible for the low prevalence 
in our population: the closeness of the community in the Kiaracondong district of 
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INTRODUCTION 
Hp is acquired mainly in childhood and is one of the most important pathogens 
for a wide spectrum of human gastrointestinal diseases, including acute and 
chronic gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue 
lymphoma (MALT) and gastric malignancy1. After detection, the bacterium should 
be eradicated, as spontaneous clearance of the infection is rare.
Consensus guidelines on treatment of Hp in adults as well as in children recommend 
7-10 day triple therapy, i.e. amoxicillin, clarithromycin or metronidazole and a 
proton pump inhibitor (PPI) in areas with clarithromycin resistance prevalences 
less than 15-20% and other regimens if the resistance rate is higher 2,3. With this 
regimen eradication rates vary from 60-90%. However, the success rate of standard 
triple therapy for Hp eradication is decreasing worldwide and is a point of concern. 
Reasons for therapeutic failure include lack of compliance to therapy and an 
increasing antimicrobial resistance of Hp to clarithromycin and/or metronidazole 
4-12. 
Resistance of Hp to clarithromycin mainly results from point mutations occurring in 
the 23S rRNA gene, and resistance to metronidazole is associated with alterations of 
the nitroreductase-encoding genes rdxA and frxA as well as an increase of the TolC 
effluxpump 13,14. Hp resistance to clarithromycin and metronidazole is thought to be 
caused by the extending use of clarithromycin for respiratory infections (especially 
in children) and the use of metronidazole for parasitic infections. Prescription of 
alternative regimens containing tetracyclines or bismuth is not allowed in children 
in many countries. Currently sequential therapy is a topic of research in adults as 
well as in children to improve the eradication rate 15-18. 
The gold standard for assessment of Hp infection is upper endoscopy plus mucosal 
biopsies of the antrum and corpus of the stomach, hereby allowing getting material 
for the urease test, histology and culture to determine the in vitro susceptibility of 
the bacteria before any treatment. Determining the in vitro susceptibility before 
starting treatment will increase the eradication rate after first treatment and seems 
to be cost effective for clarithromycin-resistant Hp 19. The additional advantage 
of endoscopy is that it can detect complications of Hp infection such as ulcer and 
carcinoma and that it is able to rule out other upper gastrointestinal disorders 
such as celiac disease, esophagitis and Crohn’s disease. However, endoscopy is an 
invasive and expensive procedure and requires the use of sedation or anesthesia 
in children. 
Dutch guidelines for adults recommend test-and-treat, which is safe and as effective 
as prompt endoscopy in absence of alarm symptoms in persons less than 45 years 
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of age 20. In the Netherlands there is also a tendency to test-and-treat Hp infection 
in children, even if the current recommendation is to perform a culture of stomach 
biopsies taken during endoscopy. According to this approach, non-invasive tests 
include antibody-based stool tests (with a sensitivity of 80-98%), the urea breath 
test and serology. However, serology does not distinguish between an active and 
a past infection 21.
In the Netherlands, data on resistance of Hp isolated from adults are only known 
between 1993 and 2003. Resistance to clarithromycin varied from 1 to 5%, while 
resistance to metronidazole was 7-31% 9,22-28. Since 2006 no further data have been 
published and resistance of Hp in children has never been investigated. The aim of 
this study was to analyze the prevalence of Hp resistance in adults and children in 
comparison to reported data on European individuals, in order to estimate whether 
the test-and-treat approach is justified in the Netherlands. 
 
MATERIAL AND METHODS
Design of the study
We conducted a single center, retrospective database study at Leiden University 
Medical Center (LUMC), the Netherlands, from January 2000 to December 2009 to 
analyze the resistance to clarithromycin and metronidazole of Hp positive cultures 
of biopsies from the gastric antrum and/or corpus of adults and children. 
Patients
The endoscopy unit of the LUMC is a reference center for family doctors as well as 
medical specialists, with a regional and national function. All consecutive patients 
that were referred for upper gastrointestinal endoscopy and had positive biopsies 
for Hp, were included. The data of all Hp-isolates were divided into two groups: 
0-17.99 years of age (children) and ≥18 years of age (adults). If later biopsies and 
positive cultures from a patient were obtained after an interval of ≥3 months, 
the results were analyzed separately, and used to estimate the development of 
resistance under appropriate treatment. In adults, information about the medical 
history was limited due to the fact that most of them had been sent for endoscopy 
by the family doctor with an incomplete history of abdominal complaints. For most 
patients it was unknown whether or not they had undergone non-invasive testing 
before, and whether or not they had been treated before. 
The children attended the outpatient department of our hospital or a regional 
hospital before endoscopy. None of the children had been treated for Hp before 
the first endoscopy. Children with a migrational background (at least one non-
Dutch parent, or adopted from abroad) were analyzed separately. 
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Culture and susceptibility testing
Cultures for Hp were carried out at the laboratory of Medical Microbiology of 
the LUMC. Biopsies from gastric antrum and corpus were sent to the laboratory 
as soon as possible in NaCl 0.9% and inoculated on a blood plate (BioMérieux, 
France) and on a specific plate for Hp, Pyloria agar (PYL-plate, Bio-Mérieux, France). 
Plates were checked after 3-5 and 7 days of incubation under microaerophilic 
circumstances. Hp positivity was determined with a Gram stain and a positive 
oxidase, katalase and urease test. Minimal inhibitory concentrations (MIC’s) were 
determined by the epsilometer test (E-test) (AB Biodisk, Solna, Sweden). Strains 
were considered clarithromycin sensitive if MIC ≤0.25 and resistant if MIC > 0.25 
mg/L and metronidazole sensitive if MIC ≤ 8mg/L, intermediate if >8 and ≤ 16 mg/L 
and resistant if > 16 mg/L, according to the Eucast-criteria (www.eucast.org). 
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Fig 1. Hp resistance to Clarithromycin and Metronidazole in 2000-2009 
in the Netherlands
Parameters Adults (N=1080)  Children (N=72)
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Table 1B. Changing resistances in second and third occasion biopsies 
R = resistant
S = sensitive
Cla = Clarithromycin. 
MNZ = Metronidazole
RESULTS
From 2000 to 2009 all Hp-positive patients who underwent endoscopy, were 
included: 72 children and 1080 adults. Of these 1152 patients, 1214 cultures were 
positive for Hp. Susceptibility of clarithromycin and metronidazole could be 
determined in 1088 (90%) and 1095 (90%) cultures, respectively. 
Demographic data and results of resistance to antibiotics are summarized in Table 
1A and Table 1B. Hp-resistance rate against clarithromycin was 8.5-9.4% in adults and 
6.5-7.2% in children. Resistance to metronidazole was observed in 20.7-22.9% of adults 
and 10.4-11.7% of children. Resistance to both clarithromycin and metronidazole 
in adults was 2.8%, equally divided among genders, and there was no time trend 
(2.9% in 2000-2004, 2.7% in 2005-2009). Double resistance to clarithromycin and 
metronidazole was absent in children. The Hp resistance rate against any antibiotic 
in the whole decade was 29.2% in adults, and 16.9% in children.
Sixty-nine percent of the children with Hp positive cultures in the study had a 
migrational background. Three out of 5 clarithromycin resistant strains of the 
children and 6 of 8 metronidazole resistant strains were detected in offspring of 
a non-Dutch mother. All clarithromycin resistant strains in children were detected 
in the period after 2004, while metronidazole resistant strains were divided 
equally over the whole period. The development of resistance to clarithromycin 
and metronidazole over time reveals that the resistance to clarithromycin slightly 
increased in the Netherlands (with the exception of the year 2009) and that 
resistance to metronidazole slightly decreased (figure 1).
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DISCUSSION
We have shown that the Hp resistance to clarithromycin in the Netherlands has 
increased from less than 5% 22,24,26-28 to 8.5-9.4% in adults. This rate is comparable 
to the resistance rates reported in the European multicenter study in 1998 9 and 
in studies from Finland, UK and Belgium in the same period 29-31. However, this 
resistance rate is low compared to increasing resistance rates to clarithromycin in 
adults in other European countries 32-36, where prevalences have been reported of 
17-26% (supporting information Table 2). In case of secondary resistance rate, the 
resistance rate can be up to 68%, as was shown in a study from France 34. We speculate 
that the most likely explanation of the low resistance rates of Hp to clarithromycin 
in the Netherlands is the relative reluctance of prescribing antibiotics by physicians 
in the Netherlands 37. The prescription of clarithromycin, the most commonly used 
macrolide in primary care, has stabilized since 2003 (www.swab/nethmap.nl).
Hp resistance to metronidazole in this study was 20.7-22.9%, while in the period 
before 2003 rates in Dutch adults varied from 7 to 33%. This, again, is comparable 
to data from Sweden (16.2%) 38 and much lower than the resistance rates in other 
European countries (27-61%) 29-36,39 and the resistance rates reported in the European 
multicentre study in adults (33.1%) 9 (Supporting information Table 2). Metronidazole 
resistance of Hp varies geographically, being higher in developing countries, where 
this class of antibiotics is frequently used to treat parasitic infections. 
Double resistance to clarithromycin and metronidazole was detected in only 2.8% 
of the strains of adults and remained stable over time. The low resistance rates to 
clarithromycin and metronidazole as well as the stable and low double resistance 
rate are remarkable, because since implementation of the stool antigen test in 2000, 
the test-and-treat regimen has been introduced gradually in the Netherlands wit-
hout determining the susceptibility of Hp before treatment. With such approach, 
one would have expected higher secondary resistance rates, since the endoscopic 
samples were probably more often from patients who failed first line therapy. Re-
sistance of Hp to amoxicillin in Europe and USA is very low and stable, and clinically 
negligible. In 1998, Glupczynski reported 0% primary resistance to amoxicillin all 
over Europe with an exception for Italy (8.2%) and Copenhagen (4%) 9. We did not 
determine the susceptibility to amoxicillin in all Hp positive strains systematically 
during the last decade.
This study is the first to report data on the antimicrobial resistance of Hp in children 
living in the Netherlands. The prevalence of Hp in young children is low (1.2%-9%) 
and most infected children are offspring of at least one non-Dutch parent 40,41. In our 
study 69% of the Hp-positive children had a migrational background. We determined 
resistance rates of 6.5-7.2% to clarithromycin and 10.4-11.7% to metronidazole. Se-
venty-five percent of the metronidazole resistant strains and sixty percent of the 
clarithromycin resistant strains were detected in offspring of a non-Dutch mother. 
The resistance rates of Hp strains of children in our study are much lower than the 
resistance rates of 24% and 25% to clarithromycin and metronidazole, respectively, 
that were detected in an European study 42, and also lower than rates reported from 
various European countries 36,43-50(Supporting information Table 3). In the European 
study, 41% of the children with resistant strains were offspring of non-European 
mothers, while double resistance to both clarithromycin and metronidazole was 
6.9%. Several studies have suggested that resistance to clarithromycin is generally 
higher in children than in adults, probably due to the previous use of macrolides in 
respiratory infections 9,30,35. However, we detected lower clarithromycin resistance 
rates in children (6.5%) compared to adults (8.5%). 
A limitation of the study is the single center design, due to unavailability of data 
on resistance rates in the past ten years and differences in testing methods and 
standardization in other centres. Therefore, geographical variation in resistance 
rates could not be analyzed. However, previous publications on Dutch adults have 
reported only a slightly different resistance pattern in diverse areas of our country 
9,22,24, although the resistance rate may be higher in an area of the country with a 
higher percentage of immigration. Another limitation is the retrospective nature 
of our study, conducted on the basis of medical files. Since general practitioners in 
the Netherlands directly refer adult patients for endoscopy, primary or secondary 
resistance could not be distinguished. In general, secondary resistance is far higher 
than primary resistance, and is one of the main reasons for eradication failures 33,35. 
Although it is likely that some of the Hp-positive patients in our study have used 
antibiotics before, and in spite of the gradual introduction of the test-and-treat-
regimen in adults in 2007 2, the resistance rates have remained low. 
The resistance rate for clarithromycin in Dutch adults below 15-20% supports the 
recommendation 2 to routinely perform a test-and-treat regimen. However, we 
believe that also in the coming years surveillance of regional Hp resistance is needed, 
and that this should be well communicated to the clinicians. Previous studies have 
shown that most physicians are insufficiently acquainted with regional resistance 
data 51-53. Up-to-date information on resistance rates is needed to timely modify 
treatment regimens. Hopefully, future development of non-invasive susceptibility 
tests for clarithromycin in stool samples will facilitate this. 
Our data on resistance rates in children suggest that also in this age group a test-
and-treat approach can be used. However, we suggest that the clinician should 
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inquire if the child has received clarithromycin in the previous 3 months, and if 
so, exchange this by metronidazole. In case of eradication failure after the first 
clarithromycin-based triple therapy, a second triple therapy with metronidazole 
instead of clarithromycin could be prescribed. A second eradication failure should 
lead to referral of the patient for endoscopy with biopsies for susceptibility testing. 
 
CONCLUSION
The resistance of Hp to clarithromycin, although still low compared to resistance in 
other European countries, is slowly increasing in Dutch adults, while the resistance 
to metronidazole has been stable. The resistance of Hp to clarithromycin and 
metronidazole in Dutch children is low compared to European data and lower 
than in adults. Double resistance to both clarithromycin and metronidazole is 
low in adults and absent in children. Both for adults and children, a test-and-treat 
approach can be used, but continuing surveillance of antibiotic resistance remains 
necessary. 
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2006 3 Sweden 333 1.5 16.2 0
2007 4 Italy 2004-2006 255 16.9 29.4
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2001 13 European 
multicenter 
study
1998 1274 9,9 33.1 0.8
Table 2 Reported prevalence of H.pylori resistance to clarithromycin (CLA)
and metronidazole (MNZ) in adults in Europe
P*: primary resistance  S**: secondary resistance






























































































16   
23 
22   
0
0
2006 25 2000-2003 58 Germany 9 16 unknown
2008 26 2002-2006 157 Italy 42 12 unknown
2007 27 1994-2005 377 France 22.8 36.7 0
2006 28 1999-2002 1233 Europe*
(Multicenter)
24 25 0.6
Table 3 Reported antibiotic resistance of H.pylori 
in children in Europe (last decade)
* no Dutch children included
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Prevalence of Hp infection
The prevalence of Hp infection varies from 11-70% in Europe to more than 90% in 
adults in Africa and Asia. This variability is highly related to geography, ethnicity, 
age and socioeconomic status. The prevalence of Hp infection has decreased 
considerably in the last decades in developed countries 1-4. Roosendaal et al 
predicted a decrease of the prevalence in Dutch adults between 1940 and 2040 
from 50% to less than 20% , based on a decrease of prevalence from 20 to 10% in the 
6-15 years age group over 15 years (1978-1993) in the Netherlands 5.
We found a relatively low prevalence in young children (2-4 years of age) in the 
general Dutch population (1.2%), and a significantly higher prevalence among 
Dutch children of the same age belonging to ethnical minorities (2.6%) (Chapter 
4). A recent study showed that Hp prevalence in Dutch children (7-9 years of age) 
has stabilized between 1993 and 2005 at a level of 9% 6. This stabilization can be 
explained in two ways. First, it may be that no further decrease can be expected 
by improving living conditions and decreasing family size because these have 
already reached the maximum level attainable. Alternatively, a potential decrease 
by improvements of these factors may be neutralized, at least partly, by increased 
immigration of children from high prevalence countries. As a result of this 
stabilization, colonization with Hp is expected to remain common in the coming 
decades 6. Notably, more than 90% of the children, investigated in this study, were 
of Dutch descent, so that the study group does not reflect the current population, 
of which 21% is reported to be of non-Dutch descent (www.cbs.nl). So, the authors 
may have underestimated the prevalence of Hp among schoolchildren of the 
general population in the Netherlands. 
During the last five years, the number of people from high prevalence countries in 
Eastern Europe (Poland, Romania, Bulgaria) and Asia and the Middle East (China, 
Afghanistan, Iran, Iraq), who immigrated into the Netherlands has tripled (www.
cbs.nl), which may have a significant influence on the Hp prevalence. Since the 
infection is usually acquired at a young age, it is likely that these immigrants and 
their offspring have already been infected in the country of origin, and form a risk 
group for Hp infection and its pathology.
After discovering that a group of adopted children that emigrated from Indonesia 
to the Netherlands tested Hp-positive, we decided to investigate the prevalence of 
Hp infection in their country of birth. We expected to find a high prevalence of Hp 
in a crowded district of Bandung (Chapter 6). Interestingly, the prevalence in the 
young Indonesian children was relatively high (8% for the youngest participants). 
ABSTRACT
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However, this could not be confirmed in a follow-up two years later when the preva-
lence was 0%. Given previous data on the prevalence of Hp in Indonesia 7, we specu-
late that the prevalence of Hp infection may differ between various areas in a coun-
try. We therefore suggest that before deciding on eradication campaigns in high 
prevalence countries, the local variation of prevalence should first be monitored.
Apart from the group of children of non-Dutch parents living in the Netherlands 
(recently immigrated or adopted from abroad), another risk group for Hp-infection 
consists of institutionalized children. The prevalence of Hp in residential children 
with developmental disabilities is reportedly higher than in the general population 
8-11. In the Netherlands the prevalence of Hp has been described by Bohmer et al 
in institutionalized persons (N=338, 11-89 year, median age 51 yr), of whom a small 
number of children 12. The Hp prevalence in these adults was significantly higher 
(83%) than the prevalence of Hp in adults of the general Dutch population (50%).
A third group we have identified to be at risk for severe Hp infection are children 
with immunodeficiencies / X-linked agammaglobulinemia (XLA), because of 
their proneness to recurrent gastrointestinal infections. Although Hp infections 
in immunocompetent children are limited to superficial infections of the 
stomach, bacteremia with Helicobacter (species) has been found in patients with 
immunodeficiencies 13,14. Diagnosis can be delayed by the fact that recognition in 
standard automatic blood cultures is problematic, since Hp germs multiply slowly. 
Therefore extended culturing after one week of incubation is often applied, if no 
bacterial growth is observed in the first week. We published a case report and 
literature review on this topic 15. 
In the 10 years database of Hp-strains from adults and children at the Leiden 
University Medical Center, the prevalence of Hp-resistance to antibiotics was low, 
despite dramatically increasing percentages of drug resistance to clarithromycin, 
metronidazole and amoxicillin reported elsewhere 16-21. Possibly, the restricted 
prescription of antimicrobial drugs and the lack of over-the-counter availability 
of antibiotics in the Netherlands may have contributed to the low prevalence 
of drug resistance. Intensive surveillance of the resistance patterns will remain 
important, given the expected changes in the composition of the population in 
the Netherlands.
With respect to the virulence of Hp strains, special attention should be given to 
children originating from high prevalence countries, for example as a result 
of adoption or immigration. This group is at increased risk of developing 
gastroduodenal lesions as they may have been infected with the more virulent 
strains (CagA positive), that are dominant in these countries. These strains cause 
more pathology, and at an earlier age 22,23. In contrast, in the Dutch population CagA 
positive strains are currently vanishing. Den Hoed et al detected CagA-seropositivity 
in only 8.2% of the Hp-positive Dutch children 6. An earlier Finnish cohort study 
determined a decline in prevalence of CagA antibodies from 43% to 8% among 
subjects 14-44 years old over a 21 year period, suggesting that CagA positive strains 
are disappearing more rapidly than CagA negative strains 24.
Prevalence of gastric and duodenal ulcers
In the prospective multicenter study on the frequency and risk factors of gastric and 
duodenal ulcers or erosions in European children undergoing an upper endoscopy, 
we found a frequency of 8.1%, occurring mainly in adolescence. However, Hp 
infection was only detected in 27% of the children with ulcer or erosion (Chapter 5). 
In an earlier multicenter study on antibiotic resistance of Hp in Europe a frequency 
of 10.4% of ulcers was found in children above the age of 12 years 25. More ulcers and/
or erosions (16.7 to 22%) were found in research centers in Belgium, Italy and Turkey. 
In all these countries the clinical presentation was similar: clinical symptoms such 
as epigastric pain, hematemesis, melena and weight stagnation, as well as known 
chronic diseases such as inflammatory bowel disease (IBD) and rheumatic diseases. 
If aged above 10 years of age, nocturnal pain was also significantly associated with 
ulcers 26. 
Oderda et al reported on Hp negative ulcers 27 and highlighted that in countries with 
a relatively low Hp prevalence most ulcers are not associated with Hp-infection. 
So, pediatricians should be aware that gastric and duodenal ulcers in European 
children, surprisingly, occur more often in Hp-negative than in Hp-positive children. 
Therefore, despite the decreasing prevalence of Hp in Europe, the frequency of 
ulcers and/or erosions may still increase due to the increasing prevalence of chronic 
diseases such as inflammatory bowel diseases (IBD) and rheumatic diseases, as well 
as the increasing use of drugs, that can cause ulcers as a side-effect (ulcerogenic 
drugs) in children. The development of gastro-duodenal ulcers is multifactorial, 
so that many other factors than Hp, such as genetic susceptibility, can lead to the 
development of ulcers. 
As mentioned above, the risk of developing peptic ulcer disease (PUD) is higher 
in pediatric and adult patients that are CagA seropositive or carry CagA positive 
status. However, not all CagA positive patients develop ulcers, depending on the 
in situ expressing of CagA. A positive correlation was established between acute 
and chronic gastritis, bacterial density and CagA-expression. Moreover, Figura et 
al showed that most patients with non-ulcer-dyspepsia harbor both CagA positive 
and –negative strains 28-31. For practical reasons, in our study the CagA status of Hp 
or other virulence factors of the bacterium in positive patients with ulcer and/or 




In the last decade, much progression has been made in the development of non-
invasive diagnostic tools. However, none of these tests are 100% specific and 
sensitive (Chapter 2) and most tests have been poorly validated in infants below the 
age of 2 years in low prevalence populations. At the present time the monoclonal 
stool test is most frequently used, and has an adequate sensitivity and specificity 
(97-98% and 95-100%, respectively) for the detection of Hp 32. Therefore easily 
accessible testing of Hp has become feasible. The 13C-urea breath test requires 
special devices and equipment for children, but provides a non-invasive test with 
an optimal performance, even better for post-treatment control. Serology testing 
is only useful in epidemiological studies, since this does not discriminate between 
a past or ongoing infection. The availability of these tests has aroused discussion 
about the necessity to perform endoscopy in suspected cases versus a test-and-
treatment regimen.
 Endoscopy versus test-and-treat: implications for the differential diagnosis
Recently, an evidence-based guideline was published for diagnosis and treatment of 
Hp infection in children in Europe and North-America. This guideline recommends 
endoscopy (including rapid urease testing, histology and/or culture) in all 
suspected cases, including those with a positive non-invasive test 33. When used in 
combination, these tests are still considered “the gold standard” for the diagnosis of 
Hp in children. The main reason for recommending endoscopy is that the symptoms 
of Hp infections are little specific, so that other causes for the symptoms of the child 
need to be ruled out (e.g. celiac disease, Crohn’s disease and gastro esophageal 
reflux). The added advantage of endoscopy is that other pathologies of the upper 
gastrointestinal tract can be found, as well as complications of the infection. 
However, there are also arguments against endoscopy. First, it is an invasive method 
that cannot be performed in children without anesthesia or deep sedation. Second, 
the diagnosis of celiac disease has become easier by recent sensitive antibody-
tests, and does no longer require taking duodenal biopsies in selected cases 34. 
Third, in children the diagnosis of Crohn’s disease is not only based on abdominal 
complaints, but also on the presence of peri anal alterations (skin tags, fistulas, 
abcess), extra-intestinal manifestations as mouth ulcers and growth retardation, 
and a positive family history for inflammatory bowel disease. Fourth, a child 
suspected for suffering from gastroesophageal reflux, is usually first empirically 
treated with antacids, proton pump inhibitors or life style intervention before 
endoscopy is considered.
In our opinion, the decision to perform endoscopy before treatment of Hp or 
not, is dependent on the information obtained at the medical history, physical 
examination and laboratory investigations. The medical history, given by the child 
and his/her parents is crucial and should include at least detailed information on 
the symptoms, family history of gastric ulcers or carcinoma, and country of birth. A 
thorough examination of the patient, accompanied by laboratory results, is required 
to assess the likelihood of the various disorders in the differential diagnosis. 
Endoscopy versus test-and-treat: implications for the therapeutic strategy
As mentioned above, the recent guideline for children recommends susceptibility 
monitoring33 before treatment, implying that endoscopy should always be 
performed. Theoretically, the obvious advantage is that if the susceptibility for 
antibiotics is known, the appropriate antibiotics can be administered. However, in 
our country this would mean that one should have to perform an endoscopy in 
all cases, as non-invasive susceptibility tests with sufficient diagnostic accuracy are 
not yet available. While the specificity of PCR in stool is high, the sensitivity is still 
too low for practical use 35-37. Susceptibility testing is more important in countries, 
where high resistance rates of Hp play a role, than in our country.
The question is if this general guideline is also applicable for the Netherlands, 
thus whether a test-and-treat regimen in Dutch children is justified instead of 
endoscopy and culture with susceptibility testing. This decision should be primarily 
based on the prevalence of resistance to antibiotics, particularly to clarithromycin. 
Therefore, it is important to collect information on the patients’ previous use of 
antibiotics, particularly regarding clarithromycin. Current guidelines for adults 
suggest susceptibility testing only if the resistance rate of Hp to clarithromycin is 
higher than 15-20% 38. Our study shows that the resistance to clarithromycin in the 
children was only 6.5% and the resistance to metronidazole 10.4%. As a result of 
the low resistance rate in children in the Netherlands, we believe that an Hp test-
and-treat regimen without susceptibility testing is justified as first-line therapy, on 
the condition that the local and national antibiotic susceptibility of Hp are being 
monitored regularly. Currently, the only way to monitor Hp resistance is to analyze 
databases from centers that perform Hp cultures from gastric biopsies. 
In conclusion, it seems justified to follow the directive for the adult test-and treat 
regimen policy, with some exceptions, for example if there are reasons to exclude 
pathology, or in acute situations (such as hematemesis or melena). In case of one 
or more risk factors (use of ulcerogenic drugs, family history of ulcers or gastric 
carcinoma), performing an endoscopy may be necessary to exclude other pathology 
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and to provide an appropriate treatment and follow-up. In case of eradication 
failure, susceptibility testing of Hp to clarithromycin would be desirable, before 
a second eradication therapy is applied. Since a non-invasive way of resistance 
testing (for example by molecular methods in feces) is still not available, in such 
cases endoscopy is advised.
8.3 TREATMENT
Considering that resistance percentages of Hp in the Netherlands are low, the most 
applied triple therapy (amoxicillin, clarithromycin and a proton pump inhibitor (PPI)) 
is generally effective in eradicating Hp. In case of previous use of clarithromycin, 
one could consider substituting clarithromycin for metronidazole. If triple therapy 
does not succeed in the first round, a regimen of amoxicillin, metronidazole and PPI 
is recommended to cover secondary resistance to clarithromycin. Clarithromycin 
resistant strains form the main cause of treatment failure, particularly in children 39. 
To a lesser extent, this is due to metronidazole resistant strains. In case of a second 
eradication failure, an alternative regimen (higher doses of the drugs 21, more drugs 
40, other drugs (such as bismuth 41 or quinolones 42), or longer duration of therapy can 
be considered. A sequential therapeutic scheme, combining a PPI and amoxicillin 
for the initial five days to reduce the bacterial load and to destroy the bacterial 
cell wall, followed by a PPI and clarithromycin and metronidazole for the remaining 
five days, could increase the eradication rate. However, evidence for sequential 
therapy to be more effective than triple therapy is lacking 43-45. The downside of 
these alternative regimens is that they may diminish patient compliance and may 
increase side effects. As the eradication rate strongly decreases after the first 
therapy, a well-tailored therapy regimen for children is important.
Recent Italian studies suggest that Hp positive immigrants probably should be 
managed differently from Italian patients 46,47, and possibly this is relevant as well 
for children in the Netherlands. For example it is unclear if in children of non-Dutch 
parents efficacy of eradication therapy is lower than in children of Dutch origin, 
because of worse compliance or by higher antibiotic resistance (Chapter 7). 
8.4 PREVENTION
In analogy to the prevention of other infectious diseases, vaccination against Hp 
has been considered. De Vries et al calculated that vaccination could possibly be a 
cost-effective intervention if the prevalence would be higher than 20% 48. However, 
these authors exclusively assessed effects 20 years or more after vaccination (such 
as ulcers and gastric cancer), while pediatricians deal with somatic consequences 
(growth, anemia) and cognitive function impairment in children with Hp infection 49-
51 over a shorter time interval. These effects are particularly worrying in developing 
countries with a relatively high prevalence.
At present, no Hp vaccine has been registered yet, but possible target groups and 
alternative strategies are being defined. Partly for this reason we assessed the 
prevalence in young children in the Netherlands in 2006. Due to the low prevalence 
of Hp in the Netherlands, we believe that general preventive measurements, such 
as vaccination, are not indicated for all children.
In recent years, interest in vaccines has declined, because of publications on adverse 
effects of Hp eradication in adults in developed countries, such as increase of 
gastroesophageal reflux disease and Barrett’s esophagus. Furthermore, it has been 
suggested that Hp eradication may contribute to the obesity epidemic and the 
increasing prevalence of asthma and allergy. Meanwhile, considerable progression 
has been made in eradication success rates 52 in developed countries and data on 
a decline of the prevalence of gastric cancer do also not speak for a vaccination 
campaign. In high-prevalence countries, however, mass vaccination against Hp 
may be an attractive and practical strategy to eliminate Hp-related disease. In some 
of these countries public health authorities have initiated programs for screening 
and eradicating of the bacterium.
Thus far, attempts to develop a good (preventive as well as curative) vaccine 
against Hp have faltered for perceptual, practical and financial reasons. Vaccine 
candidates, delivery routes and adjuvants for preventive and therapeutic strategies 
were investigated in experimentally infected mice with significant reductions in Hp 
colonization, but only few of these studies achieved complete Hp eradication 53. In 
humans, few clinical vaccination studies have been performed and the results have 
been disappointing 52,54. Moreover, the genetic diversity of Hp (sometimes within 
a single patient) forms a complicating factor. A few years ago, however, a phase 
1 study with clinical testing of a vaccine was published with promising results. All 
healthy non-infected volunteers responded to one or two of the three recombinant 
antigens (VacA, CagA and NAP) and in 86% of cases the vaccine mounted IgG 
antibody responses to all of these. Booster immunization after 2 years elicited a 
strong antibody response to the three antigens in all subjects. The safety of this 
intramuscular vaccine was satisfactory 55. However, no further publications on this 
topic in Hp infected persons have been published by the same research group.
8.5 CONCLUSIONS OF THIS THESIS
In this dissertation we present the results of our research on Helicobacter pylori in-
fections in childhood, focusing on the prevalence, diagnosis and treatment of the 
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infection. Our studies were conducted in the Netherlands, Europe and Indonesia. 
We discuss diagnostic tests, therapeutic regimens, resistance and preventive mea-
surements. We highlight clinical and pathophysiological aspects of the infection 
and describe which particular strains are prevalent and how transmission occurs. 
Presently, there are no established correlations between a Helicobacter pylori infec-
tion and recurrent abdominal pain, gastroesophageal reflux disease or growth retar-
dation. We present data on the prevalence of Helicobacter pylori in young infants in 
the Netherlands and observe that children with at least one non-Dutch parent form a 
risk group. We assess risk factors in a Europe-wide study on gastroduodenal erosions 
and ulcers in childhood. In our study, Helicobacter pylori infection and gastrotoxic 
medications were relatively little implicated as etiology of that pathology. The preva-
lence of Helicobacter pylori infection in Indonesian young children is relatively high 
and points at an early acquisition of the infection. Finally, the resistance of Helicobac-
ter pylori to clarithromycin and metronidazole was assessed for adults and children 
in the Netherlands. Low resistance rates were found, but the resistance in adults is 
increasing. We conclude that a test-and-treat regimen is justified for the Netherlands.
8.6 TOPICS FOR FUTURE RESEARCH 
1.  In the Netherlands the prevalence of Hp infection in children is low, so screening 
and treating is probably not useful. Exceptions should be made for identified 
risk groups. So far, in the Netherlands research in institutionalized individuals 
has only been carried out in studies on adults, in which some children have 
been included. We believe that the prevalence of Hp should be determined 
among children in institutions for disabled persons, as they live closely together 
and possibly part of their abdominal and/or nutritional complaints are caused 
by Hp infection. A gain in the quality of life in those children may be obtained 
by eradicating Hp.
2.  Multicenter studies in children with primary or secondary immunodeficiencies 
are desirable. It is presently unknown what the prevalence is of Hp in these 
children. They often need intensive care nursing and ulcerogenic medication. 
Scientific studies should be initiated to investigate whether test-and-treat 
regimen can prevent ulcers and bacteremia in the therapeutic pathway of these 
children. Within this group of patients particular attention should be drawn to 
children of non-Dutch parents from high-prevalence countries.
3  In most Dutch children suspected for Hp infection a test-and-treat-regimen is 
justified. Exceptions are children with acute presentations of the disease, such 
as hematemesis or melena or children with eradication failure. A prospective 
study on the effects of such strategy should be performed.
4.  Regular local surveillance of antibiotic resistance of Hp in adults and children 
is necessary for optimal treatment and prevention of eradication failure and 
secondary antibiotic resistance.
5.  In future Dutch guidelines on treatment of children with Hp infection, the choice 
of antibiotics should be tailored, depending of the development of resistance of 
Hp to clarithromycin and metronidazole in the Netherlands and the resistance 
rate in the country of birth of the infected children and their parents.
6.  The development of a sensitive and specific non-invasive susceptibility test for 
Hp in stool samples would be a significant improvement of the management of 
children with suspected Hp infection before first triple therapy as well as after 
failure of eradication.
7.  Pediatric-based Hp research is necessary for our understanding of both clinical 
and pathophysiological aspects of the infection. Since the prevalence of Hp in 
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In this thesis the prevalence, diagnosis and treatment of Helicobacter pylori (Hp) 
infection in children are discussed. 
Chapter 1 is a general introduction to the subject: it describes the history, clinical 
features such as transmission and virulence factors, gastrointestinal and extra-in-
testinal symptoms, as well as the diagnosis, epidemiology, reinfection and sponta-
neous clearance of the infection. Some aspects of current guidelines for diagnosis 
and treatment are discussed as well as the increasing prevalence of resistance to 
antibiotics. 
Section A: Reviews 
In Chapter 2 the developments on Helicobacter pylori in children are discussed for 
the time frame April 2005 until March 2006. The Canadian Helicobacter Study Group 
Consensus Conference published their evidence-based evaluation of the approach 
to Helicobacter pylori infection in children and adolescents that was later adopted 
by the Pediatric Task Force in the USA. Various diagnostic tools for Helicobacter 
pylori infection in children were compared, such as the urea breath test, stool tests, 
monoclonal and polyclonal tests, as well as newly introduced rapid tests, urine test 
and serology. Increasing resistance of Hp in children led to the introduction of novel 
therapeutic schemes, for example sequential therapy (omeprazole plus amoxicillin, 
followed by omeprazole plus clarithromycin and tinidazole) instead of conventional 
triple therapy. At the time, extra-digestive manifestations of Hp in children were not 
yet documented sufficiently. During the period of the review the Nobel Prize was 
awarded for the discovery of Helicobacter pylori, and its role in gastritis and peptic 
ulcer disease and this led to a renewed interest in the field. 
Chapter 3 provides a review of the advances in pediatric Helicobacter pylori 
infections from April 2009 - March 2010. Studies on genetic variability between 
adult and childhood Hp-isolates did not establish a correlation between CagA, 
VacA and the histopathology in children. There was no association of Hp and some 
extra-intestinal manifestations as recurrent abdominal pain, gastroesophageal 
reflux disease and growth retardation. However, the guidelines on Hp screening in 
children with those symptoms were contradictory. 
The emergence of Hp-negative duodenal and gastric ulcers in children was noted 
and led to the European multicenter pilot study on ulcers/and erosions, described 
in chapter 5. The number of publications on drug resistance had increased enor-
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in other countries and are compatible with a test-and-treat regimen for both adults 
and children in the Netherlands.
Chapter 8 comprises the general discussion and conclusions of this thesis. It also 
provides an outlook for future research on Hp infection in children. 
Summary 
mously up to 2010 and this increase has continued since. We concluded that the 
results of studies on sequential therapy were too variable to adopt this new first-
line eradication regimen for children. No benefits were found for probiotic adminis-
tration on Hp eradication in children. Vaccination studies were performed dealing 
with the way of administration of the vaccine, the efficacy and the cost-benefit and 
the translation of studies from mice to humans.
Section B: Prevalence
Chapter 4. In view of the generally early acquisition of Hp infection, we studied the 
prevalence of Hp infection in young children living in the Netherlands. Prevalences 
were very low (1.2%), with a significant difference between the children with parents 
who are both Dutch (0.5%) and children with at least one non-Dutch parent (2.6%). 
The frequency of Hp in children with parents from the three largest immigrants 
groups in the Netherlands (originating from Suriname, Morocco and Turkey) was 
5.3%. Therefore, children belonging to the aforementioned groups are at a relatively 
high risk and would benefit most from early diagnosis and treatment.
Chapter 5 describes the results of a prospective European multicenter study on the 
frequency and risks of gastric and duodenal ulcers or erosions in children. The study 
showed a frequency of 8.1% of ulcers and/or erosions, mainly appearing during 
teenage years. It appeared that an Hp infection was implicated less frequently as a 
cause of this pathology than expected.
Chapter 6 reports a follow-up study on the prevalence of Helicobacter pylori 
infection in young children living in Bandung, Indonesia. The prevalence of Hp 
in the age-group 3-9 months was 8%, indicative of a very early acquisition of 
the infection. However, two years later all children tested negative. This chapter 
also discusses the limitations of the diagnostic test, the role of breastfeeding in 
prevention and (spontaneous) clearance of the infection. 
Section C: Diagnosis
Chapter 7 deals with Hp resistance related issues. The antimicrobial resistance of 
Hp was determined in a 10-year’s retrospective database study at Leiden University 
Medical Center, the Netherlands. Resistance to clarithromycin was detected in 
8.5-9.4% of the Hp isolates of adults and in 6.5-7.2% of the children, respectively. 
Resistance to metronidazole was detected in 20.7-22.9% of the adults and 10.4-11.7% 





Dit proefschrift beschrijft het onderzoek, dat ik als kinderarts-maag-, darm- 
en leverziekten heb gedaan over de besmetting met en behandeling van de 
Helicobacter pylori infectie bij kinderen. Doel van het onderzoek was om de kennis 
van de infectie met deze bacterie en de daarmee verband houdende onderwerpen 
als de prevalentie, het stellen van de diagnose en de behandeling te vergroten. 
Wij voorzagen dat de kinderarts een belangrijke rol speelt bij deze relatief nieuw 
ontdekte infectieziekte, aangezien deze in de jeugd wordt opgedaan, zonder 
behandeling levenslang aanwezig blijft en tot ernstige ziekte kan leiden. 
In de praktijk leidt dit tot de vraag of het zinvol is om de besmetting te voorkomen 
(bijvoorbeeld door vaccinatie) of ongedaan te maken (door te screenen en te 
behandelen). Richtlijnen hierover zijn niet eensluidend en niet zomaar te vertalen 
naar de Nederlandse situatie. Om hier zorgvuldig mee om te gaan hebben we 
Sectie A van dit proefschrift, “Wetenschappelijke vorderingen ten aanzien van 
Helicobacter pylori”, gewijd aan de internationale ontwikkelingen betreffende de 
infectie bij kinderen in de tijdsintervallen 2005-2006 en 2009-2010. Een belangrijk 
aspect in de literatuur van beide intervallen was de ontluikende resistentievorming 
van de bacterie tegen antibiotica.
Hoewel Helicobacter pylori wereldwijd voorkomt en meer dan 50% van de bevolking 
ermee besmet is, zijn er grote lokale verschillen: in Nederland komt de infectie 
relatief weinig voor. Immigratie vanuit landen met een hogere infectiegraad, 
zoals Turkije, Marokko, Suriname en Somalië of adoptie heeft echter gevolgen 
(gehad) voor de besmettingsgraad in Nederland. Aangezien de infectie meestal op 
kinderleeftijd plaatsvindt en door één van de ouders wordt overgedragen, hebben 
wij deze specifieke groepen kinderen apart onderzocht. 
In Sectie B van dit proefschrift, “De Helicobacter pylori infectie in verschillende 
omgevingen” bespreken we onze bevindingen over de infectie bij kinderen in 
Nederland, in Europa en in een relatief arm district in Indonesië. We hebben niet 
alleen voor het eerst vastgesteld, dat besmetting ook in Nederland al op zeer jonge 
leeftijd optreedt, maar ook dat de besmetting vaak pas in de puberteit gerelateerd 
kan worden aan ernstige ziektebeelden. Met ons langetermijn-onderzoek in 
Indonesië kon het fenomeen, dat spontaan klaren van de infectie mogelijk is, in 
kaart worden gebracht. In een unieke Europese studie is het mogelijk gebleken, om 
de infectie in diverse landen te bestuderen en een relatie te leggen met ernstige 
verschijnselen op de kinderleeftijd.
Naar aanleiding van de in sectie A geconstateerde toenemende resistentievorming 
van de bacterie elders in de wereld, hebben we het in Sectie C “Diagnostiek van 
Helicobacter pylori infectie” beschreven onderzoek verricht. We onderzochten het 
resistentiepatroon van in Leiden gekweekte Helicobacter pylori- stammen tegen 
de twee antibiotica, die het meest voor de behandeling van de infectie gebruikt 
worden. Met de resultaten van dit onderzoek konden we een behandelingsstrategie 
vaststellen voor Helicobacter-positieve kinderen in Nederland.
Het proefschrift wordt afgesloten met Sectie D “Algemene Discussie”. Dit gedeelte 
is onder meer bedoeld om onze bevindingen te relateren aan de praktijk van 
behandeling van kinderen met een Helicobacter pylori infectie.
Hieronder treft u een korte samenvatting aan per hoofdstuk.
Hoofdstuk 1 is een algemene inleiding tot het onderwerp: het beschrijft de 
geschiedenis van Helicobacter pylori, de klinische kenmerken zoals transmissie en 
virulentiefactoren, en de symptomen die de bacterie kan geven op het gebied van 
het maag-darmkanaal en daarbuiten. Ook het stellen van de diagnose en diverse 
aspecten van epidemiologie, reïnfectie en het spontaan klaren van de infectie 
worden besproken. Bovendien worden aanbevelingen uit recente richtlijnen voor 
de diagnose en behandeling belicht, evenals het probleem van de toenemende 
resistentieontwikkeling voor antibiotica. 
Sectie A: Wetenschappelijke vorderingen ten aanzien van Helicobacter pylori
In Hoofdstuk 2 worden de ontwikkelingen besproken zoals die in de literatuur be-
schreven worden tussen april 2005 en april 2006. In die periode publiceerde de Ca-
nadese Helicobacter pylori werkgroep richtlijnen voor een Helicobacter pylori infectie 
bij kinderen en adolescenten. Deze richtlijnen werden later in de Verenigde Staten 
overgenomen door de “Werkgroep voor kinderen met een Helicobacter-infectie”. 
Verschillende diagnostische methoden werden vergeleken: in uitademingslucht, 
ontlasting, urine en bloed. Resistentieontwikkeling tegen antibiotica leidde tot 
nieuwe behandelingsregimes zoals sequentietherapie (bestaande uit een maag-
zuurremmer met één antibioticum gedurende enkele dagen, gevolgd door een 
maagzuurremmer met twee andere antibiotica in de dagen daarna) in plaats van de 
traditionele drievoudige therapie (een kuur van 7-10 dagen met een maagzuurrem-
mer en daarbij twee dezelfde antibiotica gedurende de hele kuur). Onderzoek liet 
nog niet voldoende aanwijzingen zien voor verschijnselen buiten het maag-darm-
kanaal bij kinderen, die veroorzaakt zouden kunnen worden door de infectie. In het 
jaar van de beschreven vorderingen werd de Nobelprijs uitgereikt aan Marshall en 
Warren voor de ontdekking in 1983 van Helicobacter pylori en de rol die de bacterie 
speelt bij maagontsteking en ulcus-ziekte. Hun eervolle erkenning leidde tot een 
hernieuwde wetenschappelijke belangstelling voor infectie met deze bacterie. 
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Hoofdstuk 3 beschouwt de wetenschappelijke voortgang over Helicobacter pylori in-
fecties bij kinderen tussen april 2009 en april 2010. In die tijdsperiode verschenen er 
studies over een mogelijk verband tussen virulentiefactoren zoals CagA en VacA en 
de microscopische bevindingen van het maagslijmvlies bij kinderen, zoals dat ook 
bestaat bij volwassenen; bij kinderen werd dit verband niet gevonden. De literatuur 
liet geen associatie zien tussen de infectie en recidiverende buikpijn, gastro-oesofa-
geale refluxziekte en achterblijvende groei. Richtlijnen over screening op Helicobac-
ter infectie van kinderen met deze symptomen waren echter niet eensluidend. Een 
in dat jaar verschenen publicatie over Helicobacter-negatieve maag- en dunnedarm-
zweren bij kinderen deed de leden van de Pediatric Task Force van de Europese 
Helicobacter pylori Studie Groep ertoe besluiten om de studie, zoals beschreven in 
hoofdstuk 5 van dit proefschrift, te starten. Het toenemend probleem van resistentie 
van de bacterie tegen antibiotica vond zijn weerslag in het grote aantal publicaties 
hierover, een trend die tot op heden voortduurt. Een gunstig effect van probiotica 
bij de behandeling van Helicobacter pylori bij kinderen kon nog niet worden aange-
toond. Er verschenen diverse vaccinatiestudies, die zich vooral richtten op de wijze 
van toediening, de efficiëntie en de kosten-batenanalyse van een eventueel vaccin 
en het extrapoleren van de onderzoeksresultaten aan muizen naar mensen.
Sectie B: De Helicobacter pylori infectie in verschillende omgevingen
Hoofdstuk 4 (Nederland). Aangezien een infectie met Helicobacter pylori meestal 
wordt verworven op kinderleeftijd, bestudeerden we de prevalentie bij jonge 
kinderen in Nederland. Deze was heel laag (1.2%) met een duidelijk verschil tussen 
kinderen van twee Nederlandse ouders (0.5%) en kinderen met minstens één 
niet-Nederlandse ouder (2.6%). De prevalentie bij kinderen met ouders uit de drie 
grootste immigrantengroepen in Nederland (Surinaams, Marokkaans en Turks) was 
5.3%. Daarom hebben kinderen, behorend tot één van die groepen een relatief 
hoog risico op een Helicobacter infectie en zouden zij het meest kunnen profiteren 
van vroege opsporing en behandeling van de infectie.
In hoofdstuk 5 (Europa) worden de resultaten beschreven van een Europese studie, 
waaraan 19 onderzoeks- en behandelcentra deelnamen. De prevalentie van en risico-
factoren voor maag- en dunnedarmzweren en erosies bij kinderen werd onderzocht. 
Wij vonden een prevalentie van 8.1%, en deze zweren en erosies bleken voorname-
lijk te ontstaan gedurende de puberteit. Tot onze verbazing waren een Helicobacter 
pylori infectie en het gebruik van bepaalde pijnstillers (NSAID), beide beschouwd 
als een belangrijke risicofactor voor maagslijmvliesschade bij zowel volwassenen 
als kinderen, minder frequent oorzaak van de zweren en erosies dan verwacht. 
Hoofdstuk 6 (Indonesië) beschrijft een follow-up onderzoek over de prevalentie van 
Helicobacter pylori infectie bij jonge kinderen in een district van Bandung op Java, 
Indonesië, gebruikmakend van een diagnostische test in de ontlasting. Wij vonden 
een prevalentie van 8% bij kinderen van 3-9 maanden oud, een bevestiging dat kin-
deren in dit gebied op zeer jonge leeftijd de infectie oplopen. Bij hernieuwd testen 
van dezelfde kinderen twee jaar later, bleek echter geen van de kinderen meer po-
sitief in de ontlastingstest. In dit hoofdstuk bespreken wij dit klaren van Helicobacter 
pylori infecties. Daarnaast richten wij ons op de beperkingen van de diagnostische 
test en de rol van borstvoeding ten aanzien van preventie van de infectie. 
Sectie C: Diagnostiek van Helicobacter pylori infectie
Hoofdstuk 7 omschrijft het resistentiepatroon van Helicobacter pylori tegen antibi-
otica. De resistentiegegevens van Helicobacter pylori werden geanalyseerd in een 
database van de afdeling Medische Microbiologie van het Leids Universitair Medisch 
Centrum (LUMC), over een verzamelperiode van 10 jaar. Resistentie tegen het anti-
bioticum clarithromycine werd in 8,5-9,4% van volwassen- en in 6,5-7,2% van kin-
derkweken aangetroffen. De resistentie tegen het antibioticum metronidazol was 
respectievelijk 20,7-22,9% in kweken van volwassenen en 10,4-11,7% in die van kin-
deren. Deze getallen zijn laag in vergelijking met bevindingen uit andere landen en 
rechtvaardigen een beleid in Nederland, waarbij de behandeling mag worden in-
gezet zonder resistentiebepaling vooraf, voor zowel volwassenen als voor kinderen.
Sectie D: Algemene beschouwing
Tot slot worden in Hoofdstuk 8 de hoofdresultaten van dit proefschrift in een 
breder perspectief geplaatst en worden suggesties gedaan voor vervolgonderzoek. 
Daarnaast biedt dit hoofdstuk een open aanbeveling aan de Nederlandse 
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Terugblikkend op een lange carrière als kinderarts, kinderarts-neonatoloog en 
kinderarts voor maag-, darm- en leverziekten, in zowel de perifere praktijk als in twee 
academische ziekenhuizen, zijn er veel mensen geweest, die hebben bijgedragen 
aan mijn academische vorming. Ik zal mij hieronder richten op diegenen, die direkt 
betrokken zijn geweest bij mijn onderzoek, waarvan dit proefschrift het resultaat is. 
Mijn promotor, Prof. dr. J.M. Wit, Jan Maarten:
je werd mijn promotor toen het meeste wetenschappelijke werk was verricht, 
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dankbaar voor je jarenlange gastvrijheid in de kinderkliniek en voor je begeleiding, 
nadat we tot de conclusie waren gekomen dat ik toch eigenlijk gewoon ‘op die 
Helicobacter moest promoveren’. Je zeer snelle beoordeling van manuscripten 
motiveerde mij enorm. Het is een grote eer tot je laatste promovendi te behoren 
en ik ben je daar heel dankbaar voor. 
Mijn copromotor, Dr. M.L.Mearin, Luisa: 
onze jarenlange samenwerking, begonnen toen je in Leiden solliciteerde, wordt 
bekroond met dit proefschrift. Ik ben er ontzettend trots op dat jij ‘mijn baas en 
opleider in de kindergastroenterologie’ hebt willen zijn en hier nu als copromotor 
optreedt. Jouw drive, vakkennis en aanmoediging zijn een belangrijk voorbeeld 
voor jonge onderzoekers, zelfs als die soms wat ouder en eigenzinniger zijn dan 
gemiddeld.
Dr. K.E. Veldkamp en Dr. E.J. Kuijper, Karin Ellen en Ed: 
bedankt voor jullie begeleiding bij het onderzoek naar de resistentie van 
Helicobacter pylori in Nederland en de prevalentie van deze bacterie bij kinderen 
in Bandung. 
Dr. D. Prasetyo en Dr. I. Rosalina, Dwi en Ina:
many thanks for your hospitality and for providing me with the opportunity to 
study the prevalence of Hp in Indonesian children. I enjoyed working with you and 
have good memories of our fieldwork in Bandung. 
De ‘gastro-groep’, Luisa, Joachim, Margreet, Maaike, Yvonne, Inge, Caroline, Sabine, 
Kimberley en Erica:
bij mijn gedeeltelijke terugkomst in het LUMC in 1994 waren we nog maar met ons 
tweeën. Inmiddels is het een echte en hechte groep met een uitstekende werksfeer, 
waarin zelfs de oudste werknemer zonder schaamte haar werkzaamheden als 
onderzoeker-in-opleiding kon verrichten. Heel veel dank daarvoor. 
Kinderkliniek LUMC: 
jullie namen mij op in jullie hechte groep in 2008 en boden mij een paar geweldige 
laatste jaren. Ik hoop dat onze jaarlijkse reünie mag blijven voortduren. 
Het secretariaat, Mirjam en haar team: 
bedankt voor de goede sfeer, jullie efficiëntie en onmisbare hulp. 
Collega-specialisten en huisartsen uit Leiderdorp, Leiden en omgeving: 
in mijn 25 jaren in het Rijnlandziekenhuis heb ik met velen van jullie intensief en 
met plezier mogen samenwerken. Ik waardeer het vertrouwen en de vriendschap 
van jullie gedurende al deze jaren.
 
Tot slot mijn familie: 
zonder grote familie is het leven saai, zeker voor Midden-Oosterse begrippen. Vaak 
heb ik jullie uitnodigingen voorbij laten gaan vanwege mijn werk, zelfs na mijn 
officiële pensioen. Ik hoop nu meer van de partij te zijn.  
Mijn ouders, die deze dag helaas niet meer kunnen bijwonen, dank ik voor de 
maximale ruimte, die ze ons hebben gegeven voor ontplooiing en gebruik van onze 
talenten. Hun trots zou grenzeloos zijn. Mijn zus: onze levens zijn uiteengelopen, 
maar dat hoeft geen belemmering te zijn om onze gemeenschappelijke roots te 
koesteren en de onderlinge band vast te houden. 
Lieve Daniël, Selma en Maurice: 
jullie hebben mij vaak moeten missen door werk, symposia of congressen, en de 
laatste periode zelfs door het schrijven. Ik hoop dat jullie samen met Judith en 
Froukje heel gelukkig worden. Ik ben heel trots op jullie.  
Last but not least, lieve Abdo: 
aan jou heb ik het aller-aller-allermeeste te danken. Het moet maar eens zwart 
op wit staan. Iemand uit het Midden-Oosten, die zoveel opoffert om zijn vrouw 
haar vervolg-opleidingen te laten doen en fulltime te laten werken, is een grote 
uitzondering. Je hebt het allemaal gedaan en het heeft nooit ter discussie gestaan. 
Dankzij jouw afzien van eigenbelang en eindeloze geduld ligt er nu ook nog dit 
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